Original Article
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
N Engl J Med 2005; 352:2271-2284June 2, 2005
- Abstract
Background
The incidence and severity of herpes zoster and postherpetic neuralgia increase with age in association with a progressive decline in cell-mediated immunity to varicella–zoster virus (VZV). We tested the hypothesis that vaccination against VZV would decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia among older adults.
Methods
We enrolled 38,546 adults 60 years of age or older in a randomized, double-blind, placebo-controlled trial of an investigational live attenuated Oka/Merck VZV vaccine (“zoster vaccine”). Herpes zoster was diagnosed according to clinical and laboratory criteria. The pain and discomfort associated with herpes zoster were measured repeatedly for six months. The primary end point was the burden of illness due to herpes zoster, a measure affected by the incidence, severity, and duration of the associated pain and discomfort. The secondary end point was the incidence of postherpetic neuralgia.
Results
More than 95 percent of the subjects continued in the study to its completion, with a median of 3.12 years of surveillance for herpes zoster. A total of 957 confirmed cases of herpes zoster (315 among vaccine recipients and 642 among placebo recipients) and 107 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among placebo recipients) were included in the efficacy analysis. The use of the zoster vaccine reduced the burden of illness due to herpes zoster by 61.1 percent (P<0.001), reduced the incidence of postherpetic neuralgia by 66.5 percent (P<0.001), and reduced the incidence of herpes zoster by 51.3 percent (P<0.001). Reactions at the injection site were more frequent among vaccine recipients but were generally mild.
Conclusions
The zoster vaccine markedly reduced morbidity from herpes zoster and postherpetic neuralgia among older adults.
Media in This Article
Figure 1
Diagram of the Study Design and Results.Figure 2
Kaplan–Meier Estimates of the Effect of Zoster Vaccine on the Cumulative Incidence of Postherpetic Neuralgia (Panel A) and Herpes Zoster (Panel B) in the Modified Intention-to-Treat Population.Article Activity
- Article
Herpes zoster, or shingles, is characterized by unilateral radicular pain and a vesicular rash that is generally limited to a single dermatome.1,2 Herpes zoster results from reactivation of latent varicella–zoster virus (VZV) within the sensory ganglia.3,4 The incidence and severity of herpes zoster increase with advancing age; more than half of all persons in whom herpes zoster develops are older than 60 years. Complications occur in almost 50 percent of older persons with herpes zoster.3-5 The most frequent debilitating complication is postherpetic neuralgia, a neuropathic pain syndrome that persists or develops after the dermatomal rash has healed.5-9 The frequency and severity of postherpetic neuralgia also increase with increasing age.9-11 The pain and discomfort associated with herpes zoster can be prolonged and disabling, diminishing the patient's quality of life and ability to function to a degree comparable to that in diseases such as congestive heart failure, myocardial infarction, diabetes mellitus type 2, and major depression.12 Antiviral therapy reduces the severity and duration of herpes zoster but does not prevent the development of postherpetic neuralgia.2,11 Postherpetic neuralgia may persist for years and is often refractory to treatment.13
Forty years ago, Hope-Simpson proposed that immunity to VZV plays a pivotal role in the pathogenesis of herpes zoster,3 and subsequent observations support the thesis that cell-mediated immunity to VZV is a major determinant of the risk and severity of herpes zoster.3,7,11,14-17 Whereas levels of antibody to VZV remain relatively constant with increasing age, the increased incidence and severity of herpes zoster and postherpetic neuralgia among older adults are closely linked to a progressive age-related decline in cell-mediated immunity to VZV.4-8,14-21 Recurrences of herpes zoster are uncommon among immunocompetent persons, presumably because an episode of herpes zoster boosts immunity to VZV, effectively “immunizing” against a subsequent episode.3,4,7,8,22
Previous studies have shown that VZV vaccines can elicit a significant increase in cell-mediated immunity to VZV in immunocompetent older adults21-25 and reduce the incidence and severity of herpes zoster in recipients of bone marrow allografts.26,27 These observations led us to hypothesize that immunization of older persons with a VZV vaccine would boost their cell-mediated immunity to VZV and thereby provide protection against herpes zoster and postherpetic neuralgia.22 The Shingles Prevention Study (Department of Veterans Affairs [VA] Cooperative Study No. 403) was conducted to determine whether vaccination with a live attenuated VZV vaccine would decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia in adults 60 years of age or older.
Methods
A detailed description of the methods used in this study is provided in the Supplementary Appendix (available with the full text of this article at www.nejm.org). A brief overview is presented here.
Study Design
We conducted a randomized, placebo-controlled, double-blind clinical trial at 22 sites, in which adults 60 years of age or older received either VZV vaccine or placebo. The study was approved by a human rights committee of the VA Cooperative Studies Program (VACSP) and by the local institutional review boards at all study sites. An independent data and safety monitoring board reviewed the safety data and the interim results.
Study Population
Eligible subjects had a history of varicella or had resided in the continental United States for at least 30 years. Immunocompromised persons and those unable to adhere to the study protocol were excluded. All subjects provided written informed consent.
Intervention
Subjects received one subcutaneous injection of 0.5 ml of the investigational live attenuated Oka/Merck VZV vaccine (“zoster vaccine”) or placebo. The estimated potency at vaccination of the 12 vaccine lots used in the study ranged from 18,700 to 60,000 plaque-forming units per dose. The median potency was 24,600 plaque-forming units, and more than 90 percent of vaccinated subjects received 32,300 plaque-forming units or less.
Follow-up
Active follow-up and ascertainment of cases of herpes zoster were ensured by an interactive automated telephone-response system, which subjects called monthly. If a subject's responses to a standardized set of questions suggested a possible case of herpes zoster, the subject was instructed to contact the local study site immediately, and a fax containing the subject's response was sent to the site. Subjects who did not call the automated telephone-response system within a pre-established length of time were called by the automated telephone-response system. If this effort to reach the subject failed, the local study site was notified by fax to contact the subject directly. At the end of the study, subjects were asked to report any previously unreported episodes of herpes zoster.
Safety Evaluation
All adverse events occurring within 42 days after vaccination were recorded. Thereafter, only serious adverse events were recorded if reported by the subject and considered by the study physician to be related to the vaccination. Deaths were identified on the basis of reports from family members and during follow-up of missed monthly calls to the automated telephone-response system.
Approximately 300 subjects at each of the study sites were enrolled in a substudy that more closely monitored adverse events. These subjects maintained a daily log of body temperature and a “report card” of symptoms related to the injection site and other clinical symptoms during the 42 days after vaccination. Thereafter, they were followed to identify all hospitalizations.
Identification and Evaluation of Suspected Cases of Herpes Zoster
At enrollment, the subjects were educated with regard to the signs and symptoms of herpes zoster. Those who had a new rash or new unilateral pain were urged to contact their study site immediately. Study personnel attempted to evaluate all subjects with new rashes as soon as possible. Subjects with unilateral rashes and no alternative clinical diagnoses were classified as having “suspected cases of herpes zoster” and were followed according to the study protocol. The evaluating physician offered subjects with clinically diagnosed herpes zoster, without cost, the licensed antiviral drug famciclovir (Famvir, SmithKline Beecham and Novartis Pharmaceuticals), in accordance with the manufacturer's recommendations, and with standard-of-care treatment for pain. Pain management was not specified by the study protocol.
Herpes zoster–associated pain (including unpleasant sensations such as allodynia and pruritus, which are not always characterized as pain by persons with herpes zoster) was measured with the use of the Zoster Brief Pain Inventory, an assessment tool in the form of a questionnaire completed by the subject that was specifically designed to measure pain and discomfort in herpes zoster.28 This questionnaire and others29,30 were used to assess the effect of herpes zoster on the subjects' activities of daily living, quality of life, and general health status. Characteristics of the rash, associated complications, and medication use were also recorded. Evaluations based on responses to the questionnaires were repeated over a period of at least 182 days, according to a schedule specified by the study protocol. Digital photographs and specimens for laboratory diagnosis were obtained from subjects with suspected cases of herpes zoster.
Confirmation of Cases
Before unblinding, each suspected case of herpes zoster was classified as a confirmed case of herpes zoster or as not a confirmed case with the use of a hierarchical algorithm that incorporated the results of the polymerase-chain-reaction (PCR) assay performed at the central laboratory of the study, virus culture at the local virology laboratory, and the final clinical diagnosis of the study's clinical evaluation committee, consisting of five physicians with expertise in herpes zoster.
The PCR assay, designed to detect and discriminate among DNA from wild-type and vaccine strains of VZV and from herpes simplex virus (HSV), could detect approximately 13 copies of DNA from wild-type or the vaccine strain of VZV. The PCR assays included primers and a probe for the human beta-globin gene to verify the presence of cellular DNA in the specimens from the lesions.
If the PCR assay revealed VZV DNA, the suspected case of herpes zoster was classified as a confirmed case; if the assay was positive for beta-globin or HSV DNA and negative for VZV DNA, the case was classified as not a case of herpes zoster. If the specimen obtained for the assay was inadequate (i.e., was negative for both viral and beta-globin DNA) or was missing, the final diagnosis was determined by the isolation of VZV or HSV in the local virology laboratory. In the absence of a valid laboratory diagnosis, the case was classified on the basis of the clinical diagnosis by the clinical evaluation committee.
Efficacy End Points
The primary end point was the burden of illness due to herpes zoster, a severity-by-duration measure of the total pain and discomfort associated with herpes zoster in the population of study subjects.28,31,32 For each confirmed case of herpes zoster, responses to the “worst pain” question in the Zoster Brief Pain Inventory were used to calculate a herpes-zoster severity-of-illness score, defined as the area under the curve (AUC) of herpes-zoster pain plotted against time during the 182-day period after the onset of rash. Subjects in whom herpes zoster developed had severity-of-illness scores ranging from 0 to 1813. Increasing mean scores are highly correlated with a decrease in the health-related quality of life and in functional status among older adults.28,33 A score of 0 was recorded for subjects in whom herpes zoster did not develop during the study period.
The “herpes-zoster burden-of-illness score” represented the average severity of illness among all subjects in the vaccine or placebo groups; it was calculated as the sum of the herpes-zoster severity-of-illness scores of all members of a group divided by the total number of subjects in the group. The secondary end point was the incidence of postherpetic neuralgia, defined as pain associated with herpes zoster that was rated as 3 or more on a scale ranging from 0 (“no pain”) to 10 (“pain as bad as you can imagine”), persisting or appearing more than 90 days after the onset of rash. Scores lower than 3 were not associated with significant decrements in the quality of life or the ability to carry out activities of daily living and were therefore not considered to represent postherpetic neuralgia.10,28
Statistical Analysis
A data-analysis plan was completed before the data were unblinded for analysis.31,34-38 The analysis was performed by the VACSP coordinating center (West Haven, Conn.), with review and approval by the executive committee of the study. Vaccine efficacy with respect to the burden of illness due to herpes zoster (VEBOI) was defined as the relative reduction in the burden-of-illness score in the vaccine group as compared with that in the placebo group and calculated as 1 – relative risk (i.e., 1 – the herpes-zoster burden-of-illness score in the vaccine group divided by the herpes-zoster burden-of-illness score in the placebo group). The prespecified criteria for the success of the vaccine with respect to the burden of illness due to herpes zoster required a VEBOI point estimate of 47 percent or more and a lower bound of the 95 percent confidence interval greater than 25 percent. A method of assessing the combined effect of disease incidence, severity, and duration, weighted for age group, was used.31
Vaccine efficacy with respect to the incidence of postherpetic neuralgia (VEPHN) was defined as the relative reduction in the incidence of postherpetic neuralgia in the vaccine group as compared with that in the placebo group. The prespecified criteria for the success of the vaccine with respect to the incidence of postherpetic neuralgia required a VEPHN point estimate of 62 percent or more and a lower bound of the 95 percent confidence interval greater than 25 percent. The VEPHN was calculated with the use of a conditional exact method weighted for age group.34-36 The VEPHN was also calculated with the use of alternative definitions of postherpetic neuralgia as pain present for more than 30, 60, 120, and 182 days after the onset of rash caused by herpes zoster. Vaccine efficacy with respect to the incidence of herpes zoster (VEHZ) was calculated similarly.
Efficacy analyses were performed with the use of a follow-up period that excluded the first 30 days after vaccination and excluded subjects who withdrew and those in whom a confirmed case of herpes zoster developed within the first 30 days after vaccination. The results were essentially unchanged when subjects in whom herpes zoster developed during the first 30 days were included. All reported P values are two-sided.
Conduct of the Study
The study was designed by the planning and executive committees of the Shingles Prevention Study Group, the members of which were selected for relevant expertise, with the support of a planning grant from the VACSP to the study chairs (details are provided in the Supplementary Appendix). Merck contributed to the planning process through two nonvoting members on these committees. The statistical methods for analyzing burden of illness were developed and published by Merck statisticians before the initiation of the study.31 The study was initiated and implemented as a VA Cooperative Study in collaboration with the National Institute of Allergy and Infectious Diseases and Merck. Merck, the holder of the investigational new drug application, participated in the organization of oversight activities and monitored the progress of the study. The Covalent Group, an independent company, was hired by Merck to monitor case report forms and adherence to the study protocol and to report to Merck and the VACSP. The participating investigators and their staff gathered the data. An unblinded statistician at the VACSP coordinating center, who was not involved in the operation of the study, presented unblinded safety data to the data and safety monitoring board.
Management and consolidation of the data were performed by the VACSP coordinating center. Data-analysis programs were developed and tested by biostatisticians and programmers at the coordinating center and at Merck. The data were analyzed at the coordinating center. The executive committee reviewed and approved the data-analysis plan and all analyses of vaccine efficacy and safety and vouches for the study's results. The writing committee, all members of which were also members of the executive committee, wrote the manuscript and takes responsibility for it.
Results
Characteristics of the Study Subjects
A total of 38,546 subjects were enrolled in the study between November 1998 and September 2001 (Figure 1Figure 1
Diagram of the Study Design and Results.). The numbers enrolled at each study site ranged from 1167 to 2508. Follow-up was completed in April 2004. The demographic characteristics of the two study groups were similar (Table 1Table 1
Baseline Characteristics of the Study Participants.). The median age in both groups was 69 years; 6.6 percent of the vaccine recipients and 6.9 percent of the placebo recipients were 80 years of age or older. At enrollment, most of the subjects had no health-related limitations on their activities (51.3 percent) or mild health-related limitations (38.6 percent). More than 95 percent of the subjects were actively followed to the end of the study (Figure 1) and completed a closeout interview. The mean duration of herpes zoster surveillance was 3.13 years (median, 3.12 years; range, 1 day to 4.90 years) with no difference in duration between the groups. Only 0.6 percent of the subjects withdrew from the study or were lost to follow-up; 4.1 percent died during the study.Confirmed Cases for the Efficacy Analyses
More than 3500 rashes that developed in subjects in each treatment group were evaluated clinically but were not considered to be suspected cases of herpes zoster. A total of 1308 subjects with suspected herpes zoster were evaluated according to the protocol (Figure 1). Among these subjects, 317 (156 in the vaccine group and 161 in the placebo group) were determined not to have herpes zoster. Of these 317 subjects, 49 had rashes that were caused by HSV (24 in the vaccine group and 25 in the placebo group). Closeout interviews did not identify any previously unreported cases of herpes zoster. Of the 1308 suspected cases of herpes zoster, the final diagnosis in 1156 cases (88.4 percent; 417 in the vaccine group and 739 in the placebo group) was based on the results of the PCR assay.
Of the 1308 suspected cases, 984 (75.2 percent) were determined to be confirmed cases. In accordance with the protocol, 24 cases were excluded from the efficacy analyses because they occurred within 30 days of vaccination (6 in the vaccine group and 18 in the placebo group) and 3 because they were a subject's second episode of herpes zoster (Figure 1). The remaining 957 confirmed cases of herpes zoster (315 in the vaccine group and 642 in the placebo group) constituted the end points of the efficacy analyses. The results of PCR testing were positive for wild-type VZV DNA in more than 93 percent of the confirmed cases of herpes zoster in each study group (Figure 1). Vaccine virus DNA was not detected in any subjects with suspected herpes zoster.
The rate of use of antiviral medication among subjects with confirmed cases of herpes zoster was similar in the two groups (87.3 percent in the vaccine group and 85.7 percent in the placebo group), as was the proportion in whom treatment was initiated within 72 hours of the onset of rash — in 64.1 percent in the vaccine group and 65.9 percent in the placebo group. The frequency of use of various medications to treat pain resulting from herpes zoster was similar in the two groups, and the average duration of the use of opioids and the average quantity of opioids used among subjects with herpes zoster were greater in the placebo group than in the vaccine group. Thus, differences in the use of pain medication did not inflate the estimates of VEBOI or VEPHN.
Burden of Illness Due to Herpes Zoster
The herpes-zoster burden-of-illness score was significantly reduced in the vaccine group as compared with the placebo group (P<0.001) (Table 2Table 2
Effect of Zoster Vaccine on the Burden of Illness in Herpes Zoster in the Modified Intention-to-Treat Population.). Overall, VEBOI was 61.1 percent (95 percent confidence interval, 51.1 to 69.1), a result that met the prespecified criteria for success. There were no significant differences in the VEBOI when the results were stratified according to sex or age (Table 2).Incidence of Postherpetic Neuralgia
There were 107 cases of postherpetic neuralgia, 27 in the vaccine group and 80 in the placebo group (0.46 case vs. 1.38 cases per 1000 person-years, respectively; P<0.001) (Table 3Table 3
Effect of Zoster Vaccine on the Incidence of Postherpetic Neuralgia in the Modified Intention-to-Treat Population.). Overall, the VEPHN was 66.5 percent (95 percent confidence interval, 47.5 to 79.2), a result that met the prespecified criteria for success. There were no significant differences in the VEPHN when the results were stratified according to sex or age (Table 3).The VEPHN did not change appreciably when postherpetic neuralgia was defined with the use of alternative cutoff times for the duration (persistence) of pain (Table 3). In a time-to-event analysis, the cumulative incidence of postherpetic neuralgia was significantly lower in the vaccine group than in the placebo group (P<0.001) (Figure 2AFigure 2
Kaplan–Meier Estimates of the Effect of Zoster Vaccine on the Cumulative Incidence of Postherpetic Neuralgia (Panel A) and Herpes Zoster (Panel B) in the Modified Intention-to-Treat Population.).Incidence of Herpes Zoster
The overall incidence of herpes zoster per 1000 person-years was significantly reduced by the zoster vaccine, from 11.12 per 1000 person-years in the placebo group to 5.42 per 1000 person-years in the vaccine group (P<0.001) (Table 2). The VEHZ was 51.3 percent (95 percent confidence interval, 44.2 to 57.6). In a time-to-event analysis, the cumulative incidence of herpes zoster was significantly lower in the vaccine group than in the placebo group (P<0.001) (Figure 2B). The VEHZ was 37.6 percent among subjects 70 years of age or older and 63.9 percent among younger subjects (P<0.001). There was no difference in VEHZ according to sex.
Duration and Severity of Herpes Zoster
The median duration of pain and discomfort among subjects with confirmed cases of herpes zoster was significantly shorter in the vaccine group than in the placebo group (21 days vs. 24 days, P=0.03). Similarly, the mean herpes-zoster severity-of-illness score (AUC) among subjects with confirmed cases of herpes zoster was significantly lower in the vaccine group than in the placebo group (141.2 vs. 180.5, P=0.008). For almost every level of the severity-of-illness score, there were fewer cases of herpes zoster in the vaccine group than in the placebo group. The effect of the zoster vaccine on the severity of illness was greater among older subjects; thus, the VEBOI, the primary end point of the study, was maintained at 55.4 percent.
Vaccine Safety in the Total Study Population
Over the entire study period, the numbers and percentages of deaths were similar in both study groups (Table 4Table 4
Adverse Events among All Subjects and among Those in the Adverse-Events Substudy.). During the first 42 days after vaccination, the number and types of serious adverse events were similar in the two groups (Table 4), as was the distribution of serious adverse events according to body system (data not shown). During this period, varicella-like rashes at the injection site occurred more frequently among those in the vaccine group than among those in the placebo group, but varicella-like rashes at other sites occurred at similar rates in the two groups (Table 4). There were 7 confirmed cases of herpes zoster in the vaccine group and 24 in the placebo group during the first 42 days after vaccination.Five subjects had serious adverse events that were assessed by site investigators as possibly vaccine-related. Two subjects had received vaccine: a 64-year-old woman who had an exacerbation of asthma two days after receiving the vaccination, and an 80-year-old man in whom symptoms of polymyalgia rheumatica developed on day 3. The remaining three subjects, all men, who had serious adverse events had received placebo: the first subject was 65 years of age and had an anaphylactoid reaction 90 minutes after receiving the vaccination (and 30 minutes after eating peanuts); the second was 69 years of age and received a diagnosis of polymyalgia rheumatica on day 15; and the third was 78 years of age and received a diagnosis of Goodpasture's syndrome on day 52.
Adverse-Events Substudy
In the adverse-events substudy, a significantly greater number of subjects in the vaccine group had one or more adverse events than in the placebo group, reflecting a greater frequency of adverse events at the injection site among subjects in the vaccine group (Table 4). In the vaccine group, the most frequent adverse events at the injection site were erythema (in 35.8 percent of the vaccine group), pain or tenderness (in 34.5 percent), swelling (in 26.2 percent), and pruritus (in 7.1 percent). No other adverse event at the injection site was observed in more than 2 percent of the vaccine recipients. Overall, the proportion of subjects with one or more systemic adverse events was similar in the two groups; however, systemic adverse events assessed as vaccine-related occurred more frequently among vaccine recipients (Table 4).
In the substudy, during the 42 days after vaccination, significantly more subjects in the vaccine group had serious adverse events than in the placebo group (1.9 percent vs. 1.3 percent, respectively; P=0.03); there were no significant differences in the distribution of serious adverse events according to body system or type of event (data not shown). A post hoc, subject-by-subject review of serious adverse events conducted by the writing committee revealed no clinically meaningful differences between the groups in the pathophysiology, nature, timing, intensity, or outcome of these events.
The number of subjects who had one or more hospitalizations was similar in the two groups. No hospitalization among subjects in either group was considered to be related to the vaccine.
Discussion
The pain and discomfort of herpes zoster and postherpetic neuralgia cause substantial morbidity among older adults.9-12,15,28 Although herpes zoster is not a reportable disease, we estimate that 1 million or more cases occur each year in the United States, a number that is likely to increase as the population ages. Thus, a means of prevention would offer important medical and economic benefits.
The zoster vaccine reduced the burden of illness due to herpes zoster among people 60 years of age or older by 61.1 percent and reduced the incidence of postherpetic neuralgia by 66.5 percent. Significant efficacy with respect to the incidence of postherpetic neuralgia was demonstrated, regardless of how postherpetic neuralgia was defined, with a trend toward greater efficacy for postherpetic neuralgia of longer duration. The vaccine also showed significant efficacy for these end points even when the results were stratified according to age and sex. Zoster vaccine also reduced the overall incidence of herpes zoster by 51.3 percent and significantly reduced the pain and discomfort among subjects in whom herpes zoster developed. Although the effect of zoster vaccine on the incidence of herpes zoster was less among older subjects than among younger subjects, the effect of the vaccine on the severity of illness was greater among older subjects, so that the VEBOI, the primary end point of the study, was maintained at 55.4 percent.
We believe that the observed efficacy of the zoster vaccine reflects its ability to boost immunity to VZV in vaccinated subjects — an issue that will require further study. The investigational zoster vaccine had low rates of serious adverse events, systemic adverse events, hospitalization, and death. Results were similar in the two study groups, and local reactions at the vaccination site were generally mild. The greater number of early cases of herpes zoster in the placebo group, as compared with the vaccine group, and the fact that no vaccine virus DNA was detected, indicate that the vaccine did not cause or induce herpes zoster.
The minimum potency of the zoster vaccine administered to subjects in the study was at least 14 times greater than the minimum potency of Varivax (Merck), the vaccine currently licensed to prevent varicella. A preliminary study indicated that potencies of this magnitude are required to elicit a significant increase in the cell-mediated immunity to VZV among older adults — hence, the need to formulate a high-potency vaccine for this study. We know of no data to suggest that the licensed varicella vaccine would be efficacious in protecting older adults from herpes zoster or postherpetic neuralgia. Thus, we do not recommend the use of the current varicella vaccine in an attempt to protect against herpes zoster and postherpetic neuralgia. The results of our study show that vaccination of immunocompetent persons 60 years of age and older with live attenuated zoster vaccine (Oka/Merck) markedly decreases the morbidity associated with herpes zoster and the incidence of postherpetic neuralgia.
Supported by the Cooperative Studies Program, Department of Veterans Affairs, Office of Research and Development; by a grant from Merck (to the Cooperative Studies Program); and by a grant from the James R. and Jesse V. Scott Fund for Shingles Research (to Dr. Oxman). The vaccine and placebo used for the study were supplied by Merck; famciclovir was supplied by SmithKline Beecham and Novartis Pharmaceuticals.
Drs. Crawford, Gershon, Griffin, Levin, Schmader, and Wright report having received consultation fees, lecture fees, or honoraria from Merck; Drs. Betts, Greenberg, Kauffman, Levin, Weinberg, and Wright report having received grant support from Merck; Drs. Annunziato, C.Y. Chan, I.S.F. Chan, Crawford, Harbecke, Keller, Silber, Simberkoff, and Wang and Ms. Williams report holding equity in Merck; Drs. Annunziato and Levin report having partial interests in relevant patents; and Drs. Annunziato, C.Y. Chan, I.S.F. Chan, Keller, Silber, and Wang are employees of Merck.
This article is dedicated to the memory of the late Edgar Hope-Simpson, whose seminal observations and prescient hypotheses on herpes zoster provided our inspiration and rationale, and to the late John Franklin Enders, who taught us what really matters.
We are indebted to the members of the data safety and monitoring board for ensuring the safety and integrity of the study for a period of six years; to the more than 38,000 subjects whose participation has been the key to the study's success; to Dr. Robert H. Friedman for expert advice regarding the automated telephone-response system; and to Professors Michiaki Takahashi and J. Edwin Seegmiller and the late Richard T. Perkin, founding president of the Varicella–Zoster Virus Research Foundation, for their encouragement.
Source Information
The authors' affiliations are listed in the Appendix.
Address reprint requests to Dr. Oxman at the Shingles Prevention Study (Mail code 111F-1), VA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161, or at mnoxman@ucsd.edu.
Other members of the Shingles Prevention Study Group are listed in the Appendix.
Appendix
The authors' affiliations are as follows: the Department of Veterans Affairs (VA) San Diego Healthcare System and the Departments of Medicine and Pathology, University of California, San Diego (M.N.O., H.M.W., J.C.G., P.A.B., R.H.); University of Colorado Health Sciences Center, Denver (M.J.L., A.W., A.R.H.); VA Cooperative Studies Program Coordinating Center, West Haven, Conn. (G.R.J., J.H.Z., P.N.P., T.C.K.); Geriatric Research, Education and Clinical Center, Durham VA Medical Center and Center for Aging, and the Department of Medicine, Duke University Medical Center, Durham, N.C. (K.E.S.); Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. (S.E.S., P.B., N.E.S., A.R.M.); St. Louis VA Medical Center and the Department of Medicine, Washington University, St. Louis (L.D.G.); VA Boston Healthcare System, Boston (R.D.A., R.P.G., D.J.C.); VA New York Harbor Healthcare System and the Department of Medicine, New York University School of Medicine, New York (M.S.S.); Columbia University, New York (A.A.G.); New Mexico VA Healthcare System, Albuquerque (L.E.D.); VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque (K.D.B.); National Institute of Allergy and Infectious Diseases, Bethesda, Md. (C.E.B.); Minneapolis VA Medical Center, Minneapolis (V.A.M.); VA Ann Arbor Healthcare System, Ann Arbor, Mich. (C.A.K.); Edward Hines Jr. VA Hospital, Chicago (C.T.P.); VA Puget Sound Healthcare System, Seattle (K.M.N.); University of Rochester Medical Center, Rochester, N.Y. (R.F.B.); Vanderbilt University Medical Center, Nashville (P.F.W., M.R.G.); Baltimore VA Medical Center, Baltimore (S.K.K.); Birmingham VA Medical Center, Birmingham, Ala. (J.W.G.); VA Palo Alto Healthcare System, Palo Alto, Calif. (J.L., M.H.); Baylor College of Medicine, Houston (W.A.K.); University of Texas Health Science Center San Antonio, San Antonio (G.E.C.); Northport VA Medical Center, Northport, N.Y. (S.S.Y., Z.L.); James A. Haley Veterans Hospital, Tampa, Fla. (J.F.T.); Lexington VA Medical Center, Lexington, Ky. (R.N.G.); Merck Research Laboratories, West Point, Pa. (P.M.K., C.Y.C., I.S.F.C., W.W.B.W., P.W.A., J.L.S.); University of California, Los Angeles, Neuropsychiatric Institute, Los Angeles (M.R.I.).
The members of the Shingles Prevention Study Group were as follows: Writing committee — M.N. Oxman (chair), R.D. Arbeit, L.D. Gelb, G.R. Johnson, M.J. Levin, K.E. Schmader, S.E. Straus, M.S. Simberkoff; Planning and executive committees — M.N. Oxman (chair), R.D. Arbeit, P. Barry, C.E. Beisel, K.D. Boardman, C.L. Colling, L.E. Davis, L.D. Gelb, A.A. Gershon, A.R. Hayward, M.R. Irwin, G.R. Johnson, M.J. Levin, P.N. Peduzzi, K.E. Schmader, M.S. Simberkoff, S.E. Straus, A. Weinberg, H.M. Williams, P.W. Annunziato, C.Y. Chan, I.S.F. Chan, S. Manoff, C.J. White; Clinical evaluation committee — L.D. Gelb, M.J. Levin, M.N. Oxman, K.E. Schmader, S.E. Straus, G.R. Johnson, H.M. Williams; Data and safety monitoring board — R. Whitley (chair), N. Blacklow, C. Crumpacker, R.H. Dworkin, J.D. Neaton, S.G. Self, J. Zaia; VACSP human rights committee, West Haven, Conn. — R. Marottoli (chair), J.C. Niederman, W. Pritchett, F. Randall, D.G. Beckwith, R.C. Feldman, W. Farrell, S. Kasl, M. Zeman, R. Mehta, H. Allore, E.B. Perry, B. Kathe, M. Coral, D. Marshall, J. Solomon; Clinical study sites (listed in descending order of the number of subjects enrolled) — Minneapolis VA Medical Center, Minneapolis: V.A. Morrison (principal investigator), D.L. Condon, G.J. Kayser, T. Knutson, E. Lorenz, R. Mahlum, S. St. Marie; VA San Diego Healthcare System, San Diego, Calif.: J.C. Guatelli, P.A. Brooks (principal investigators), D.J. Beck, B.J. Blood, R. Bourne, J. Hutsell, S. Johns, A.D. Lucko, P. McCook, D. Ram, S.L. Smith; Durham VA Medical Center, Durham, N.C.: K.E. Schmader (principal investigator), T. Alexander-Howard, L. Folsom, N. Hampshire, J. Smith, V. Willi; University of Colorado Health Sciences Center, Denver: M.J. Levin (principal investigator), D. Barber, J. Block, N. Lang, L. Murray, S. Narro; VA Ann Arbor Healthcare System, Ann Arbor, Mich.: C.A. Kauffman (principal investigator), M. Ford, D. Hammer, M. Pesti, J.P. Thompson; Edward Hines Jr. VA Hospital, Chicago: C.T. Pachucki (principal investigator), J. Leal, M. Poly Samuel, D. Terry, N. Villanueva, S. Wood; VA Puget Sound Healthcare System, Seattle: K.M. Neuzil (principal investigator), P. Cleary, K. Greer, J. M. Laguire, K. Margulies, M. Moroz, J.A. Zuydhoek Nicholas; St. Louis VA Medical Center, St. Louis: L. Gelb (principal investigator), C. Bodicky, E.A. Clark, L. Conwill, R.E. Davis, C. Goessling; New Mexico VA Healthcare System, Albuquerque: L.E. Davis, M.K. King (principal investigators), M. Bowles, M. Estrada, K. Falkenberg, A. Garduno, J.E. Jones; University of Rochester Medical Center, Rochester, N.Y.: R.F. Betts (principal investigator), E. Barker, B. Fernaays, B. Mahoney, J. Marianacci; Vanderbilt University Medical Center, Nashville: P.F. Wright, M.R. Griffin (principal investigators), P. Chapin, L. Craddock, T. McMinn, C. Meisch, B. Redd, C. Robbins, J.Sanders; National Institutes of Health, Bethesda, Md.: P. Brunell, N.E. Soto, A.R. Marques (principal investigators), C. Groden, P. Hohman, C. Jones, M. Kelly, R. McCown, E. Meshesha, M. Raj, V. Koneti Rao; Baltimore VA Medical Center, Baltimore: S.K. Keay (principal investigator), C. Boyce, T. Bremer, K.B. Haymart, N.D. Lamb, J. Murray; VA Boston Healthcare System, Boston: R.D. Arbeit, R.P. Goodman, D.J. Cotton (principal investigators), J. Ambrosino, M. Campasano, I. Cook, D.J. Cowan, S.A. Davis, Jr., B. Dionian, C. Flemming, R.Serrao, J. Strymish, D. Syat; Birmingham VA Medical Center, Birmingham, Ala.: J.W. Gnann, Jr. (principal investigator), L. Davis, M.S. Holloway, J. Moody, P. Pappas, T. Reynolds, M. Salvaggio, N. Story, L.J. Williams; VA Palo Alto Healthcare System, Palo Alto, Calif.: J. Loutit, M. Holodniy (principal investigators), D. Cowley, S.C. Ezeji-Okoye, V.L. Faria, K.F. Kodair, S.M. Rios; Baylor College of Medicine, Houston: W.A. Keitel (principal investigator), C.B. Dyer, H. El-Sahli, R.J. Hamill, P. Holder, K. Humphrey, I. Leonard, C. Tajonera, J. Wells; VA New York Harbor Healthcare System (New York campus), New York: M.S. Simberkoff (principal investigator), J.P. Adams, S. Diaz, D. Head, M.M. Lacher; University of Texas Health Science Center San Antonio, San Antonio: G.E. Crawford (principal investigator), S. Andrews, S. Campbell, D. Hicks, C. Revado, P. Shope, K. Summers; Northport VA Medical Center, Northport, N.Y.: S. Yeh, V.E. Jimenez, Z. Lobo (principal investigators), S. Chien, L. Donnelly, B. Lorenzo, S. Lovitt, J.M. Schanfeld, M.C. Stanganelli, A. Zias; James A. Haley Veterans Hospital, Tampa, Fla.: J.F. Toney (principal investigator), J. Kirk, D. Kuziel, R. Morales, J.H. Stocks, M. Walker; Lexington VA Medical Center, Lexington, Ky.: R.N. Greenberg (principal investigator), J. Cox, K. Damron, L. Danko, N. Johnson, D. Meade, T.R. Mucci, J. Peake; VA Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven: G.R. Johnson (study biostatistician), M. Antonelli, D. Collins, P. Collins, R. Concepcion, C. Cushing, K.. Dellert, K. DiBenedetto, A. Hudson, B.J. Huff, T.C. Kyriakides, K. Newvine, P. O'Brien, V. McBride, S. O'Neil, P.N. Peduzzi, J. Vitale, T. Warholak, D. Wood, J.H. Zhang; VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, N.M.: K.D. Boardman, C.L. Colling, B. Del Curto, R.W. Fetter, J. Peterson, M.R. Sather; VA Office of Research and Development, Washington, D.C.: D. Deykin, J. Feussner, S. Fihn, B. Schuster, P. Lavori, S. Berkowitz, J. Gough, G. Huang; Study chair's office, VA San Diego Healthcare System, San Diego, Calif.: M.N. Oxman (study chair), H.M. Williams (national study coordinator), A.E. Kendall, S. Markum, J. Pettiford; Central Diagnostic Laboratory VA San Diego Healthcare System, San Diego, Calif.: R. Harbecke, Y. Naidu, L.J. Wopschall; Central Cell-Mediated Immunity Laboratory, University of Colorado Health Sciences Center, Denver: A.R. Hayward, A. Weinberg, D. Elizabeth, L. Enomoto, M. Jones; Central Cell-Mediated Immunity Laboratory, San Diego VA Healthcare System, San Diego, Calif.: H.A. Stanley, P. Jordan; Merck Research Laboratories, West Point, Pa.: K. Abraham, K. Adair, L. Amornwichet, P. Annunziato, D. Anzalone, B. Arnold, N. Brown, P. Brownell, M. Bulotsky, M. Caulfield, C.Y. Chan, I.S.F. Chan, F. Chen, C. Cheney, K. Chirgwin, J. Chodakewitz, S. Ci, J. Clair, K. Coll, S. Cook, P. Coplan, D. Cromley, C. Durkan, L. Eaton, J. Field, T. Fitzgerald, J. Ginanni, E. Giuliani, C. Gracin, D. Gutsch, A. Harmon, K. Hencken, J. Heyse, L. Hostelley, C. Ip, H. Joseph, J. Kang, R. Kaufhold, P.M. Keller, B. Lang, L. Levit, S. Lewis, S. Li, J. Liu, J. Lou, R. Lowry, S. Manoff, R. Marchese, H. Matthews, T. Morley, K. Murray, A. Ngai, A. Nikas, C. O'Brien, G. Pannicke, N. Patel, K. Perrin, L. Petruhkin, S. Ptyza, J. Rafter, V. Rednar, B. Rich, L. Rubinstein, K. Russell, R. Rutledge, J. Ryan, P. Saddier, J. Sadoff, K. Schlienger, F. Schödel, S. Senior, A. Shaw, T. Sheehan, J. Silber, J. Smith, Y. Su, T. Sterling, D. Stinson, S. Sutradhar, M.E. Thompson, R. Vessey, H. Wang, J. Wang, W. Wang, R. Wasserman, M. Waters, D. Weiss, C.J. White, M. Wooters, J. Xu; Study monitoring — Covalent Group, Wayne, Pa; VACSP Good Clinical Practice Monitoring (SMART), Albuquerque, N.M.: C. Haakenson, C. Colling, D. Krueger, and L. Taylor.
- References
References
1
Head H ,Campbell AW . The pathology of herpes zoster and its bearing on sensory localization. Brain 1900;23:353-523
CrossRef | Web of Science2
Gnann JW Jr ,Whitley RJ . Herpes zoster. N Engl J Med 2002;347:340-346
Full Text | Web of Science | Medline3
Hope-Simpson RE . The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20
Medline4
Weller TH . Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 1983;309:1434-1440
Full Text | Web of Science | Medline5
Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella zoster virus: virology and clinical management. Cambridge, England: Cambridge University Press, 2000:246-75.
6
Burgoon CF Jr ,Burgoon JS ,Baldridge GD . The natural history of herpes zoster. JAMA 1957;164:265-269
Web of Science | Medline7
Ragozzino MW ,Melton LF III ,Kurland LT ,Chu CP ,Perry HO . Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61:310-316
Web of Science | Medline8
Donahue JG ,Choo PW ,Manson JE ,Platt R . The incidence of herpes zoster. Arch Intern Med 1995;155:1605-1609
CrossRef | Web of Science | Medline9
Dworkin RH ,Portenoy RK . Pain and its persistence in herpes zoster. Pain 1996;67:241-251
CrossRef | Web of Science | Medline10
Hope-Simpson RE . Postherpetic neuralgia. J R Coll Gen Pract 1975;25:571-575
Medline11
Kost RG ,Straus SE . Postherpetic neuralgia -- pathogenesis, treatment, and prevention. N Engl J Med 1996;335:32-42
Full Text | Web of Science | Medline12
Lydick E ,Epstein RS ,Himmelberger D ,White CJ . Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995;45:Suppl 8:S52-S53
Web of Science | Medline13
Dworkin RH ,Schmader KE . The treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003;36:877-882
CrossRef | Web of Science | Medline14
Dolin R ,Reichman RC ,Mazur MH ,Whitley RJ . NIH conference: herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med 1978;89:375-388
Web of Science | Medline15
Galil K ,Choo PW ,Donahue JG ,Platt R . The sequelae of herpes zoster. Arch Intern Med 1997;157:1209-1213
CrossRef | Web of Science | Medline16
Wilson A ,Sharp M ,Koropchak CM ,Ting SF ,Arvin AM . Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-126
CrossRef | Web of Science | Medline17
Buchbinder SP ,Katz MH ,Hessol NA , et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-1156
CrossRef | Web of Science | Medline18
Miller AE . Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980;30:582-587
Web of Science | Medline19
Berger R ,Florent G ,Just M . Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981;32:24-27
Web of Science | Medline20
Burke BL ,Steele RW ,Beard OW ,Wood JS ,Cain TD ,Marmer DJ . Immune response to varicella-zoster in the aged. Arch Intern Med 1982;142:291-293
CrossRef | Web of Science | Medline21
Levin MJ ,Murray M ,Rotbart HA ,Zerbe GO ,White J ,Hayward AR . Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992;166:253-259
CrossRef | Web of Science | Medline22
Oxman MN . Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45:Suppl 8:S41-S46
Web of Science | Medline23
Levin MJ ,Barber D ,Goldblatt E , et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998;178:Suppl 1:S109-S112
CrossRef | Web of Science | Medline24
Levin MJ ,Smith JG ,Kaufhold RM , et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:1336-1344
CrossRef | Web of Science | Medline25
Trannoy E ,Berger R ,Hollander G , et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18:1700-1706
CrossRef | Web of Science | Medline26
Redman RL ,Nader S ,Zerboni L , et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997;176:578-585
CrossRef | Web of Science | Medline27
Hata A ,Asanuma H ,Rinki M , et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002;347:26-34
Full Text | Web of Science | Medline28
Coplan PM ,Schmader K ,Nikas A , et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004;5:344-356
CrossRef | Web of Science | Medline29
Ware J Jr ,Kosinski M ,Keller SD . A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233
CrossRef | Web of Science | Medline30
Brazier J ,Jones N ,Kind P . Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993;2:169-180
CrossRef | Web of Science | Medline31
Chang MN ,Guess HA ,Heyse JF . Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med 1994;13:1807-1814
CrossRef | Web of Science | Medline32
Lydick E ,Epstein RS ,Himmelberger D ,White CJ . Area under the curve: a metric for patient subjective responses in episodic diseases. Qual Life Res 1995;4:41-45
CrossRef | Web of Science | Medline33
Daut RL ,Cleeland CS ,Flanery RC , et al. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983;17:197-210
CrossRef | Web of Science | Medline34
Guess HA ,Lydick EG ,Small RD ,Miller LP . Epidemiologic programs for computers and calculators: exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data. Am J Epidemiol 1987;125:340-347
Web of Science | Medline35
Guess HA ,Thomas JE . A rapidly converging algorithm for exact binomial confidence intervals about the relative risk in follow-up studies with stratified incidence-density data. Epidemiology 1990;1:75-77
CrossRef | Medline36
Martin DO ,Austin H . Exact estimates for a rate ratio. Epidemiology 1996;7:29-33
CrossRef | Web of Science | Medline37
Hochberg Y . A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-802
CrossRef | Web of Science38
Miettinen O ,Nurminen M . Comparative analysis of two rates. Stat Med 1985;4:213-226
CrossRef | Web of Science | Medline
- Citing Articles (376)
Citing Articles
1
Miguel R Sanchez, Scott B Drutman. (2012) Current topics in infectious diseases of the skin. Expert Review of Dermatology 7:1, 93-106
CrossRef2
K. E. Schmader, M. J. Levin, J. W. Gnann, S. A. McNeil, T. Vesikari, R. F. Betts, S. Keay, J. E. Stek, N. D. Bundick, S.-C. Su, Y. Zhao, X. Li, I. S. F. Chan, P. W. Annunziato, J. Parrino. (2012) Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years. Clinical Infectious Diseases
CrossRef3
H.-t. Li, S. Lu, J.-m. Liu. (2012) Herpes Zoster Vaccination in People Aged 50-59 Years. Clinical Infectious Diseases
CrossRef4
Harriet J. Forbes, Sara L. Thomas, Sinéad M. Langan. (2012) The Epidemiology and Prevention of Herpes Zoster. Current Dermatology Reports
CrossRef5
J. BILCKE, B. OGUNJIMI, C. MARAIS, F. DE SMET, M. CALLENS, K. CALLAERT, E. VAN KERSCHAVER, J. RAMET, P. VAN DAMME, P. BEUTELS. (2012) The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiology and Infection1-14
CrossRef6
Robert W Johnson, Kazuo Higa. (2012) Prevention of herpes zoster pain. Pain Management 2:1, 63-69
CrossRef7
Roman Chlibek, Ioana Anca, Francis André, Milan Čižman, Inga Ivaskeviciene, Atanas Mangarov, Zsófia Mészner, Penka Perenovska, Marko Pokorn, Roman Prymula, Darko Richter, Nuran Salman, Pavol Šimurka, Eda Tamm, Goran Tešović, Ingrid Urbancikova, Dace Zavadska, Vytautas Usonis. (2012) Adult vaccination in 11 Central European countries – Calendars are not just for children. Vaccine
CrossRef8
Mélanie Drolet, Myron J. Levin, Kenneth E. Schmader, Robert Johnson, Michael N. Oxman, David Patrick, Simon Olivier Fournier, James A. Mansi, Marc Brisson. (2012) Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study. Vaccine
CrossRef9
Kati Lukas, Alexander Edte, Isabelle Bertrand. (2011) The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Journal of Public Health
CrossRef10
Jessica Robinson-Papp, Ik Lin Tan, David M. Simpson. (2011) Neuromuscular complications in HIV: effects of aging. Journal of NeuroVirology
CrossRef11
Paul R. Kinchington, William F. Goins. (2011) Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. Journal of NeuroVirology
CrossRef12
Albert J. M. van Wijck, Mark Wallace, Nagy Mekhail, Maarten van Kleef. 2011. Herpes Zoster and Post-Herpetic Neuralgia. , 137-144.
CrossRef13
Paul O. Hernandez, Saba Javed, Natalia Mendoza, Whitney Lapolla, Lindsey D. Hicks, Stephen K. Tyring. (2011) Family history and herpes zoster risk in the era of shingles vaccination. Journal of Clinical Virology 52:4, 344-348
CrossRef14
Gitte Vrelits Sørensen, Steen Rosthøj, Morten Würtz, Tore Kristian Danielsen, Henrik Schrøder. (2011) The epidemiology of herpes zoster in 226 children with acute lymphoblastic leukemia. Pediatric Blood & Cancer 57:6, 993-997
CrossRef15
Chien-Chun Kuo, Chien-Te Lee, I-Ming Lee, Shu-Chen Ho, Chun-Yuh Yang. (2011) Risk of Herpes Zoster in Patients Treated With Long-term Hemodialysis: A Matched Cohort Study. American Journal of Kidney Diseases
CrossRef16
B. P. Yawn. (2011) Post-Shingles Neuralgia by Any Definition Is Painful, but Is It PHN?. Mayo Clinic Proceedings 86:12, 1141-1142
CrossRef17
M. Klompas, M. Kulldorff, Y. Vilk, S. R. Bialek, R. Harpaz. (2011) Herpes Zoster and Postherpetic Neuralgia Surveillance Using Structured Electronic Data. Mayo Clinic Proceedings 86:12, 1146-1153
CrossRef18
Didier Bouhassira, Olivier Chassany, Jacques Gaillat, Thomas Hanslik, Odile Launay, Claude Mann, Christian Rabaud, Olivier Rogeaux, Christophe Strady. (2011) Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50years in general practice. PAIN
CrossRef19
Joost N. Vermeulen, Joep M.A. Lange, Stephen K. Tyring, Patrick H. Peters, Margaret Nunez, Gregory Poland, Myron J. Levin, Carrie Freeman, Ira Chalikonda, Jianjun Li, Jeffrey G. Smith, Michael J. Caulfield, Jon E. Stek, Ivan S.F. Chan, Rupert Vessey, Florian P. Schödel, Paula W. Annunziato, Katia Schlienger, Jeffrey L. Silber. (2011) Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine
CrossRef20
Christine Meyer, Amelia Kerns, Alex Barron, Craig Kreklywich, Daniel N. Streblow, Ilhem Messaoudi. (2011) Simian varicella virus gene expression during acute and latent infection of rhesus macaques. Journal of NeuroVirology
CrossRef21
Stefan Palmason, Francisco M. Marty, Nathaniel S. Treister. (2011) How Do We Manage Oral Infections in Allogeneic Stem Cell Transplantation and Other Severely Immunocompromised Patients?. Oral and Maxillofacial Surgery Clinics of North America 23:4, 579-599
CrossRef22
Peter Tanuseputro, Brandon Zagorski, Kevin J. Chan, Jeffrey C. Kwong. (2011) Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 29:47, 8580-8584
CrossRef23
M. Aubert, H. Aumaître, J. Beytout, K. Bloch, D. Bouhour, P. Callamand, C. Chave, J. Cheymol, B. Combadière, A. Dahlab, F. Denis, L. De Pontual, B. Dodet, M.-A. Dommergues, V. Dufour, A. Gagneur, J. Gaillat, J. Gaudelus, G. Gavazzi, Y. Gillet, C. Gras-le-Guen, H. Haas, T. Hanslik, I. Hau-Rainsard, S. Larnaudie, O. Launay, M. Lorrot, P. Loulergue, D. Malvy, S. Marchand, G. Picherot, D. Pinquier, C. Pulcini, C. Rabaud, F. Regnier, P. Reinert, C. Sana, C. Savagner, B. Soubeyrand, J.-L. Stephan, C. Strady. (2011) Actualités en matière de vaccination. Archives de Pédiatrie 18:11, 1234-1246
CrossRef24
B. P. Yawn, P. Wollan, J. St. Sauver. (2011) Comparing Shingles Incidence and Complication Rates From Medical Record Review and Administrative Database Estimates: How Close Are They?. American Journal of Epidemiology 174:9, 1054-1061
CrossRef25
PATRICIA O'MALLEY. (2011) Just Say No to Shingles! The Zoster Vaccine. Clinical Nurse Specialist 25:6, 281-283
CrossRef26
Joke Bilcke, Christiaan Marais, Benson Ogunjimi, Lander Willem, Niel Hens, Philippe Beutels. (2011) Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine
CrossRef27
Atika Benbernou, Mélanie Drolet, Myron J. Levin, Kenneth E. Schmader, Michael N. Oxman, Robert Johnson, David Patrick, Stéphanie Camden, James A. Mansi, Marc Brisson. (2011) Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. European Journal of Pain 15:10, 1100-1106
CrossRef28
Neelofar Ghaznawi, Ajoy Virdi, Amir Dayan, Kristin M. Hammersmith, Christopher J. Rapuano, Peter R. Laibson, Elisabeth J. Cohen. (2011) Herpes Zoster Ophthalmicus: Comparison of Disease in Patients 60 Years and Older Versus Younger than 60 Years. Ophthalmology 118:11, 2242-2250
CrossRef29
Albert Jan van Hoek, Alessia Melegaro, Nigel Gay, Joke Bilcke, W. John Edmunds. (2011) The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine
CrossRef30
Danelle Cayea, Elizabeth Eckstrom, Colleen Christmas. (2011) Update in Geriatric Medicine. Journal of General Internal Medicine
CrossRef31
Stanley A. Plotkin, Susan L. Plotkin. (2011) The development of vaccines: how the past led to the future. Nature Reviews Microbiology
CrossRef32
Joke Bilcke, Benson Ogunjimi, Frank Hulstaert, Pierre Van Damme, Niel Hens, Philippe Beutels. (2011) Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?. Vaccine
CrossRef33
M. Salleras, A. Domínguez, N. Soldevila, A. Prat, P. Garrido, N. Torner, E. Borrás, L. Salleras. (2011) Contacts with children and young people and adult risk of suffering herpes zoster. Vaccine 29:44, 7602-7605
CrossRef34
M. Assi, S. Abou Antoun. (2011) Unusual neurologic manifestations of varicella zoster virus infection with the absence of rash in a kidney transplant recipient. Transplant Infectious Disease 13:5, 545-547
CrossRef35
Hung Fu Tseng, Amy Liu, Lina Sy, S Michael Marcy, Bruce Fireman, Eric Weintraub, James Baggs, Sheila Weinmann, Roger Baxter, James Nordin, Matthew F. Daley, Lisa Jackson, Steven J Jacobsen, . (2011) Safety of Zoster Vaccine in Adults from a Large Managed Care Cohort: A Vaccine Safety Datalink Study. Journal of Internal Medicineno-no
CrossRef36
Ian H Frazer, Myron J Levin. (2011) Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Current Opinion in Virology 1:4, 268-279
CrossRef37
J.M. Bayas, R. Gil, A. Llupiá, C. Díez, A. Conesa, C. Ariza, A. Gil, M. San Martín. (2011) Hospitalizaciones por herpes zoster y neuralgia postherpética en Cataluña, 1998–2003. Vacunas 12:4, 122-128
CrossRef38
J.R. de Juanes, P. Arrazola, A. García de Codes, C. Ariza, R. Gil, M. San Martín, A. Gil. (2011) Hospitalizaciones por herpes zoster y neuralgia postherpética en la Comunidad de Madrid, 1998–2003. Vacunas 12:4, 129-135
CrossRef39
L. Salleras, A. Domínguez, E. Borrás, N. Soldevila. (2011) Eficacia protectora de las vacunas y efectividad de las vacunaciones: Introducción a la medición de la protección directa e indirecta. Vacunas 12:4, 136-146
CrossRef40
A. A. Gershon. (2011) The History and Mystery of VZV in Saliva. Journal of Infectious Diseases 204:6, 815-816
CrossRef41
Graciela Andrei, Robert Snoeck. (2011) Emerging drugs for varicella-zoster virus infections. Expert Opinion on Emerging Drugs 16:3, 507-535
CrossRef42
S. Augustine, R. A. Bonomo. (2011) Taking stock of infections and antibiotic resistance in the elderly and long-term care facilities: A survey of existingand upcoming challenges. European Journal of Microbiology and Immunology 1:3, 190-197
CrossRef43
Lawrence R. Stanberry, Richard Strugnell. (2011) Vaccines of the future. Perspectives in Vaccinology 1:1, 151-199
CrossRef44
D. Gilden, R. Mahalingam, M. A. Nagel, S. Pugazhenthi, R. J. Cohrs. (2011) Review: The neurobiology of varicella zoster virus infection. Neuropathology and Applied Neurobiology 37:5, 441-463
CrossRef45
G. Bohelay, M. Rafaa, J.-L. Caravias, M.-L. Sigal. (2011) Prise en charge symptomatique de la douleur neuropathique en dermatologie : application aux algies postzostériennes. Annales de Dermatologie et de Vénéréologie 138:8-9, 610-619
CrossRef46
J.-H. Kang, J.-J. Sheu, S. Kao, H.-C. Lin. (2011) Increased Risk of Multiple Sclerosis Following Herpes Zoster: A Nationwide, Population-Based Study. Journal of Infectious Diseases 204:2, 188-192
CrossRef47
Gisèle Pickering, Alain Leplege. (2011) Herpes Zoster Pain, Postherpetic Neuralgia, and Quality of Life in the Elderly. Pain Practice 11:4, 397-402
CrossRef48
P.-O. Lang, J.-P. Michel. (2011) Herpes zoster vaccine: What are the potential benefits for the ageing and older adults?. European Geriatric Medicine 2:3, 134-139
CrossRef49
Joseph A. Nicholas, William J. Hall. (2011) Screening and Preventive Services for Older Adults. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:4, 498-508
CrossRef50
L. Salleras. (2011) Carga del herpes zoster en España. Vacunas 12:3, 83-85
CrossRef51
M.J. Álvarez-Pasquín, M.L. Morató, A. Sampedro, M. San-Martín. (2011) Perception of herpes zoster in the general population. Vacunas 12:3, 86-94
CrossRef52
Wynnis L. Tom, Sheila Fallon Friedlander. 2011. Viral Exanthems. , 49.1-49.21.
CrossRef53
Simone Thomas, Wolfgang Herr. (2011) Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation. Immunotherapy 3:6, 771-788
CrossRef54
David R.P. Guay. (2011) Geriatric Pharmacotherapy Updates. The American Journal of Geriatric Pharmacotherapy 9:3, 204-210
CrossRef55
D. L. Pierson, S. K. Mehta, D. Gilden, R. J. Cohrs, M. A. Nagel, D. S. Schmid, S. K. Tyring. (2011) Varicella Zoster Virus DNA at Inoculation Sites and in Saliva After Zostavax Immunization. Journal of Infectious Diseases 203:11, 1542-1545
CrossRef56
Anne Louise Oaklander. (2011) Neuropathic Itch. Seminars in Cutaneous Medicine and Surgery 30:2, 87-92
CrossRef57
B. P. Yawn, P. C. Wollan, M. J. Kurland, J. L. St. Sauver, P. Saddier. (2011) Frequency of Herpes Zoster Recurrence-Reply-I. Mayo Clinic Proceedings 86:6, 586-587
CrossRef58
A. Volpi, A. Gatti, F. Pica. (2011) Frequency of Herpes Zoster Recurrence. Mayo Clinic Proceedings 86:6, 586-586
CrossRef59
Robert H. Dworkin, Christopher J. Panarites, Edward P. Armstrong, Daniel C. Malone, Sissi V. Pham. (2011) Healthcare Utilization in People with Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy. Journal of the American Geriatrics Society 59:5, 827-836
CrossRef60
Michael R. Irwin, Myron J. Levin, Carmen Carrillo, Richard Olmstead, Anne Lucko, Nancy Lang, Michael J Caulfield, Adriana Weinberg, Ivan S.F. Chan, Jim Clair, Jeff G. Smith, R.D. Marchese, Heather M. Williams, Danielle J. Beck, Patricia T. McCook, Gary Johnson, Michael N. Oxman. (2011) Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain, Behavior, and Immunity 25:4, 759-766
CrossRef61
Hung Fu Tseng, Ning Smith, Lina S. Sy, Steven J. Jacobsen. (2011) Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 29:20, 3628-3632
CrossRef62
Lang Kau, Cheryl A. Sadowski, Christine Hughes. (2011) Vaccinations in older adults: Focus on pneumococcal, influenza and herpes zoster infections. Canadian Pharmacists Journal 144:3, 132-141
CrossRef63
A. JARDINE, S. J. CONATY, H. VALLY. (2011) Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization?. Epidemiology and Infection 139:05, 658-665
CrossRef64
M. Aubert, H. Aumaître, J. Beytout, K. Bloch, D. Bouhour, P. Callamand, C. Chave, J. Cheymol, B. Combadière, A. Dahlab, F. Denis, L. De Pontual, B. Dodet, M.-A. Dommergues, V. Dufour, A. Gagneur, J. Gaillat, J. Gaudelus, G. Gavazzi, Y. Gillet, C. Gras-le-Guen, H. Haas, T. Hanslik, I. Hau-Rainsard, S. Larnaudie, O. Launay, M. Lorrot, P. Loulergue, D. Malvy, S. Marchand, G. Picherot, D. Pinquier, C. Pulcini, C. Rabaud, F. Regnier, P. Reinert, C. Sana, C. Savagner, B. Soubeyrand, J.-L. Stephan, C. Strady.. (2011) Actualités en matière de vaccination. Médecine et Maladies Infectieuses 41:5, 278-290
CrossRef65
Micha Löbermann, Denise Boršo, Inken Hilgendorf, Carlos Fritzsche, Uwe K. Zettl, Emil C. Reisinger. (2011) Immunization in the adult immunocompromised host. Autoimmunity Reviews
CrossRef66
Esther Sacoun. (2011) Actualités sur les nouveaux vaccins antiviraux : grippe, papillomavirus, zona. Actualités Pharmaceutiques 50:505, 38-39
CrossRef67
Ning Chen, Qifu Li, Yun Zhang, Muke Zhou, Dong Zhou, Li He, Li He. 2011. Vaccination for preventing postherpetic neuralgia. .
CrossRef68
Emily Eshleman, Aamir Shahzad, Randall J Cohrs. (2011) Varicella zoster virus latency. Future Virology 6:3, 341-355
CrossRef69
Trudy N Small, Morton J Cowan. (2011) Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases. Expert Review of Clinical Immunology 7:2, 193-203
CrossRef70
Esther Sacoun. (2011) Actualités sur les nouveaux vaccins antiviraux : grippe, papillomavirus, zona. Option/Bio 22:450, 4-5
CrossRef71
Susan Fitzgerald. (2011) Herpes Zoster Vaccine Might Work Even Better Than Originally Thought. Neurology Today 11:3, 1
CrossRef72
Srinivasan Sanjay, Philemon Huang, Raghavan Lavanya. (2011) Herpes Zoster Ophthalmicus. Current Treatment Options in Neurology 13:1, 79-91
CrossRef73
J. Leung, R. Harpaz, N.-A. Molinari, A. Jumaan, F. Zhou. (2011) Herpes Zoster Incidence Among Insured Persons in the United States, 1993-2006: Evaluation of Impact of Varicella Vaccination. Clinical Infectious Diseases 52:3, 332-340
CrossRef74
S.A. Pergam, C.W. Forsberg, M.J. Boeckh, C. Maynard, A.P. Limaye, A. Wald, N.L. Smith, B.A. Young. (2011) Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transplant Infectious Disease 13:1, 15-23
CrossRef75
Peng-jun Lu, Gary L. Euler, Rafael Harpaz. (2011) Herpes Zoster Vaccination Among Adults Aged 60 Years and Older, in the U.S., 2008. American Journal of Preventive Medicine 40:2, e1-e6
CrossRef76
Anne A. Gershon. 2011. Chickenpox, Measles, and Mumps. , 661-705.
CrossRef77
Albert J. M. van Wijck, Mark Wallace, Nagy Mekhail, Maarten van Kleef. (2011) 17. Herpes Zoster and Post-Herpetic Neuralgia. Pain Practice 11:1, 88-97
CrossRef78
V. Failla, A.F. Nikkels. (2011) Ustekinumab and Herpes Zoster. Dermatology 222:2, 119-122
CrossRef79
Robert W. Hurley, Heidi V. Goldstein, James P. Rathmell. 2011. Painful peripheral neuropathies. , 386-394.
CrossRef80
Kenneth E. Schmader, Robert H. Dworkin. 2011. Herpes zoster and postherpetic neuralgia. , 358-364.
CrossRef81
Bernhard Ultsch, Anette Siedler, Thorsten Rieck, Thomas Reinhold, Gérard Krause, Ole Wichmann. (2011) Herpes zoster in Germany: Quantifying the burden of disease. BMC Infectious Diseases 11:1, 173
CrossRef82
R. Pesek, R. Lockey. (2011) Vaccination of adults with asthma and COPD. Allergy 66:1, 25-31
CrossRef83
Christina Jensen-Dahm, Michael C Rowbotham, Haatem Reda, Karin Petersen. (2011) Effect of a single dose of pregabalin on herpes zoster pain. Trials 12:1, 55
CrossRef84
Jie Zhang, Elizabeth Delzell, Fenglong Xie, John W Baddley, Claire Spettell, Raechele M Mcmahan, Joaquim Fernandes, Lang Chen, Kevin Winthrop, Jeffrey R Curtis. (2011) The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Research & Therapy 13:5, R174
CrossRef85
Maria A. Nagel, Don Gilden, Ravi Mahalingam, Randall J. Cohrs. 2011. Neurologic Manifestations of Herpes Zoster. , 497-520.
CrossRef86
Anna MZ Gagliardi, Brenda Nazaré Gomes Silva, Maria R Torloni, Bernardo Soares, Anna MZ Gagliardi. 2010. Vaccines for preventing herpes zoster in older adults. .
CrossRef87
Benoit Arnould, Khadra Benmedjahed, Jean-Luc Gallais, Patrick Giniès, Ralf Baron. (2010) The impact of herpes zoster and subsequent chronic pain on patients’ daily lives. Journal of Public Health 18:6, 567-574
CrossRef88
Ting-Ting Wu, Marcia A. Blackman, Ren Sun. (2010) Prospects of a novel vaccination strategy for human gamma-herpesviruses. Immunologic Research 48:1-3, 122-146
CrossRef89
Mark S. Wallace, Gordon Irving, Verne E. Cowles. (2010) Gabapentin Extended-Release Tablets for the Treatment of Patients with Postherpetic Neuralgia. Clinical Drug Investigation 30:11, 765-776
CrossRef90
S. Gonzalez Chiappe, M. Sarazin, C. Turbelin, A. Lasserre, C. Pelat, I. Bonmarin, O. Chosidow, T. Blanchon, T. Hanslik. (2010) Herpes zoster: Burden of disease in France. Vaccine 28:50, 7933-7938
CrossRef91
Gordon Irving. (2010) The Placebo Response. Clinical Drug Investigation 30:11, 739-748
CrossRef92
Mélanie Drolet, Marc Brisson, Kenneth Schmader, Myron Levin, Robert Johnson, Michael Oxman, David Patrick, Stéphanie Camden, James A. Mansi. (2010) Predictors of Postherpetic Neuralgia Among Patients With Herpes Zoster: A Prospective Study. The Journal of Pain 11:11, 1211-1221
CrossRef93
Liyuan Ma, Ronald R. White, Siva Narayanan, Kenneth E. Schmader. (2010) Economic Burden of Herpes Zoster Among Skilled Nursing Facility Residents in the United States. Journal of the American Medical Directors Association
CrossRef94
Turna LaNeigh Harkness. (2010) Why Should Older Adults Receive the Shingles Vaccine?. Journal of Gerontological Nursing 36:10, 51-55
CrossRef95
Katherine J. Bangen, Lisa Delano-Wood, Christina E. Wierenga, Nikki H. Stricker, John R. Hesselink, Mark W. Bondi. (2010) Dementia Following Herpes Zoster Encephalitis. The Clinical Neuropsychologist 24:7, 1193-1203
CrossRef96
Sinéad Feeney, Eavan Muldoon, Patrick Barrett, Ramon Martos, Niall Mulvihill, Darina O’Flanagan, Colm Bergin. (2010) Varicella infection and the impact of late entry into the Irish healthcare system. Journal of Infection and Public Health 3:3, 106-112
CrossRef97
V. Manzano, P. Ruiz, M. Torres, F. Gomez. (2010) Severe pneumonia by aciclovir-resistant varicella-zoster virus during etanercept therapy. Rheumatology 49:9, 1791-1793
CrossRef98
Giorgio Cruccu, Andrea Truini. (2010) Neuropathic pain and its assessment. Surgical Oncology 19:3, 149-154
CrossRef99
Kenneth E. Schmader, Gary R. Johnson, Patricia Saddier, Maria Ciarleglio, William W.B. Wang, Jane H. Zhang, Ivan S.F. Chan, Shing-Shing Yeh, Myron J. Levin, Ruth M. Harbecke, Michael N. Oxman, . (2010) Effect of a Zoster Vaccine on Herpes Zoster-Related Interference with Functional Status and Health-Related Quality-of-Life Measures in Older Adults. Journal of the American Geriatrics Society 58:9, 1634-1641
CrossRef100
V. Traina-Dorge, B. Pahar, P. Marx, P. Kissinger, D. Montefiori, Y. Ou, W.L. Gray. (2010) Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. Vaccine 28:39, 6483-6490
CrossRef101
Roy Fried. (2010) Zoster Vaccine in Older Adults. Journal of the American Geriatrics Society 58:9, 1799-1800
CrossRef102
Ralf Baron, Andreas Binder, Gunnar Wasner. (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology 9:8, 807-819
CrossRef103
Thomas Weinke, Alexander Edte, Sonja Schmitt, Kati Lukas. (2010) Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey. Journal of Public Health 18:4, 367-374
CrossRef104
Ana M Bertoli, Graciela S Alarcón. (2010) Perspectives on the management of late-onset systemic lupus erythematosus. Aging Health 6:4, 475-480
CrossRef105
Dahlene Fusco, Peter Krawitz, Philip LaRussa, Sharon Steinberg, Anne Gershon, Jonathan Jacobs. (2010) VZV meningitis following varicella vaccine. Journal of Clinical Virology 48:4, 275-277
CrossRef106
Karin L. Petersen, Michael C. Rowbotham. (2010) Natural history of sensory function after herpes zoster. PAIN 150:1, 83-92
CrossRef107
Kumi Ueno-Yamamoto, Keiko Tanaka-Taya, Hiroshi Satoh, Kazuko Araki, Mitsuo Kaku, Nobuhiko Okabe. (2010) THE CHANGING SEROEPIDEMIOLOGY OF VARICELLA IN JAPAN. The Pediatric Infectious Disease Journal 29:7, 667-669
CrossRef108
T. Jelinek. (2010) Impfprävention bei chronischen Erkrankungen. Prävention und Gesundheitsförderung 5:S1, 5-9
CrossRef109
Vincent Morelli, Erick Calmet, Varalakshmi Jhingade. (2010) Alternative Therapies for Common Dermatologic Disorders, Part 1. Primary Care: Clinics in Office Practice 37:2, 269-283
CrossRef110
S.W. Wassilew, P. Wutzler. (2010) Schutz vor Zoster. Prävention und Gesundheitsförderung 5:S1, 23-27
CrossRef111
Richard Mills, Stephen K. Tyring, Myron J. Levin, Janie Parrino, Xiaoming Li, Kathleen E. Coll, Jon E. Stek, Katia Schlienger, Ivan S.F. Chan, Jeffrey L. Silber. (2010) Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 28:25, 4204-4209
CrossRef112
Miriam Wittek, Hans Wilhelm Doerr, Regina Allwinn. (2010) Varizellen und Herpes zoster. Medizinische Klinik 105:6, 399-403
CrossRef113
J. G. Donahue, B. A. Kieke, P. M. Gargiullo, A. O. Jumaan, N. R. Berger, J. S. McCauley, E. A. Belongia. (2010) Herpes Zoster and Exposure to the Varicella Zoster Virus in an Era of Varicella Vaccination. American Journal of Public Health 100:6, 1116-1122
CrossRef114
Hyong Jin Cho, Helen Lavretsky, Richard Olmstead, Myron Levin, Michael N. Oxman, Michael R. Irwin. (2010) Prior Depression History and Deterioration of Physical Health in Community-Dwelling Older Adults—A Prospective Cohort Study. American Journal of Geriatric Psychiatry 18:5, 442-451
CrossRef115
Miriam Wittek, Hans Wilhelm Doerr, Regina Allwinn. (2010) Varizellen und Herpes zoster. Medizinische Klinik 105:5, 334-338
CrossRef116
Myron J. Levin, Anne A. Gershon, Robert H. Dworkin, Marc Brisson, Lawrence Stanberry. (2010) Prevention strategies for herpes zoster and post-herpetic neuralgia. Journal of Clinical Virology 48, S14-S19
CrossRef117
Wim Opstelten, Janet McElhaney, Birgit Weinberger, Anne Louise Oaklander, Robert W. Johnson. (2010) The impact of varicella zoster virus: Chronic pain. Journal of Clinical Virology 48, S8-S13
CrossRef118
Richard J. Whitley, Antonio Volpi, Mike McKendrick, Albert van Wijck, Anne Louise Oaklander. (2010) Management of herpes zoster and post-herpetic neuralgia now and in the future. Journal of Clinical Virology 48, S20-S28
CrossRef119
A. Gatti, F. Pica, M.T.Y. Boccia, F. De Antoni, A.F. Sabato, A. Volpi. (2010) No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia. Journal of Medical Virology 82:6, 1007-1011
CrossRef120
Marc Brisson, Gurgen Melkonyan, Melanie Drolet, Gaston De Serres, Roseline Thibeault, Philippe De Wals. (2010) Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine 28:19, 3385-3397
CrossRef121
Won Suk Choi, Ji Yun Noh, Joong Yeon Huh, Yu Mi Jo, Jacob Lee, Joon Young Song, Woo Joo Kim, Hee Jin Cheong. (2010) Disease burden of herpes zoster in Korea. Journal of Clinical Virology 47:4, 325-329
CrossRef122
Alexander Ademokun, Yu-Chang Wu, Deborah Dunn-Walters. (2010) The ageing B cell population: Composition and function. Biogerontology 11:2, 125-137
CrossRef123
Z. GAO, H. F. GIDDING, J. G. WOOD, C. R. MacINTYRE. (2010) Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. Epidemiology and Infection 138:04, 457
CrossRef124
Aruna P.N. Ambagala, Tammy Krogmann, Jing Qin, Lesley Pesnicak, Jeffrey I. Cohen. (2010) A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture. Virology 399:2, 194-200
CrossRef125
Robert H. Dworkin, Daniel C. Malone, Christopher J. Panarites, Edward P. Armstrong, Sissi V. Pham. (2010) Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs. The Journal of Pain 11:4, 360-368
CrossRef126
J. Breuer, C. Grose, P. Norberg, G. Tipples, D. S. Schmid. (2010) A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008. Journal of General Virology 91:4, 821-828
CrossRef127
Joel V Chua, Wilbur H Chen. (2010) Herpes zoster vaccine for the elderly: boosting immunity. Aging Health 6:2, 169-176
CrossRef128
J. C. Sterling. 2010. Virus Infections. , 1-81.
CrossRef129
C. B. Archer, D. J. Eedy. 2010. The Skin and the Nervous System. , 1-25.
CrossRef130
Jitendra Ganju. 2010. Size of Clinical Trials. .
CrossRef131
Gérard Mick. (2010) Vaccination: a new option to reduce the burden of herpes zoster. Expert Review of Vaccines 9:3s, 31-35
CrossRef132
Robert W Johnson. (2010) Herpes zoster and postherpetic neuralgia. Expert Review of Vaccines 9:3s, 21-26
CrossRef133
Montse Tuset, Ester López-Suñé, Carlos Cervera, Asunción Moreno, José M. Miró. (2010) Características de los fármacos antivíricos frente a virus del grupo herpes actualización 2009. Enfermedades Infecciosas y Microbiología Clínica 28:3, 199.e1-199.e33
CrossRef134
Turo J. Nurmikko. 2010. Postherpetic Neuralgia. , 222-236.
CrossRef135
Yung-Hsiu Lin, Li-Min Huang, I-Shou Chang, Fang-Yu Tsai, Chun-Yi Lu, Pei-Lan Shao, Luan-Yin Chang. (2010) Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 28:5, 1217-1220
CrossRef136
I. Ridda, C.R. MacIntyre, R.I. Lindley, T.C. Tan. (2010) Difficulties in recruiting older people in clinical trials: An examination of barriers and solutions. Vaccine 28:4, 901-906
CrossRef137
C. B. Archer. 2010. , 1.
CrossRef138
Justin Bendig, Fiona Sindall. (2010) Chickenpox at Ninety Four: A Case for Extending the Use of Varicella Vaccine in the UK. Case Reports in Medicine 2010, 1-3
CrossRef139
Sally L. Hodder, Debra Chew, Shobha Swaminathan. 2010. Adult Immunization in Women and Men. , 563-582.
CrossRef140
Mike W. McKendrick, Pat Ogan, Chris C. Care. (2009) A 9 year follow up of post herpetic neuralgia and predisposing factors in elderly patients following herpes zoster. Journal of Infection 59:6, 416-420
CrossRef141
Naruhito Otani, Koichi Baba, Toshiomi Okuno. (2009) Interferon-γ release assay: A simple method for detection of varicella-zoster virus-specific cell-mediated immunity. Journal of Immunological Methods 351:1-2, 71-74
CrossRef142
Mehdi Najafzadeh, Carlo A. Marra, Eleni Galanis, David M. Patrick. (2009) Cost Effectiveness of Herpes Zoster Vaccine in Canada. PharmacoEconomics 27:12, 991-1004
CrossRef143
Nozomu Toyama, Kimiyasu Shiraki, . (2009) Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. Journal of Medical Virology 81:12, 2053-2058
CrossRef144
Genlin Ji, Jiyuan Niu, Yuxiang Shi, Lichao Hou, Yan Lu, Lize Xiong. (2009) The Effectiveness of Repetitive Paravertebral Injections with Local Anesthetics and Steroids for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes Zoster. Anesthesia & Analgesia 109:5, 1651-1655
CrossRef145
Catherine Amlie-Lefond, Burk Jubelt. (2009) Neurologic manifestations of varicella zoster virus infections. Current Neurology and Neuroscience Reports 9:6, 430-434
CrossRef146
Rachel Civen, Sandra S. Chaves, Aisha Jumaan, Han Wu, Laurene Mascola, Paul Gargiullo, Jane F. Seward. (2009) The Incidence and Clinical Characteristics of Herpes Zoster Among Children and Adolescents After Implementation of Varicella Vaccination. The Pediatric Infectious Disease Journal 28:11, 954-959
CrossRef147
Chunbo Li, Jun Xia, Jijun Wang, Chunbo Li. 2009. Risperidone dose for schizophrenia. .
CrossRef148
Alessandro Meduri, Pier Luigi Grenga, Stephen Charles Kaufman. (2009) Herpes zoster ophthalmicus. Expert Review of Ophthalmology 4:5, 537-545
CrossRef149
M. B. Mustafa, P. G. Arduino, S. R. Porter. (2009) Varicella zoster virus: review of its management. Journal of Oral Pathology & Medicine 38:9, 673-688
CrossRef150
C. McGuigan, J. Balzarini. (2009) FV100 as a new approach for the possible treatment of varicella-zoster virus infection. Journal of Antimicrobial Chemotherapy 64:4, 671-673
CrossRef151
(2009) References. Bone Marrow Transplantation 44:8, 537-557
CrossRef152
Ada Delaney, Lesley A. Colvin, Marie T. Fallon, Robert G. Dalziel, Rory Mitchell, Susan M. Fleetwood-Walker. (2009) Postherpetic neuralgia: From preclinical models to the clinic. Neurotherapeutics 6:4, 630-637
CrossRef153
Marcie Tomblyn, Tom Chiller, Hermann Einsele, Ronald Gress, Kent Sepkowitz, Jan Storek, John R. Wingard, Jo-Anne H. Young, Michael A. Boeckh. (2009) Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biology of Blood and Marrow Transplantation 15:10, 1143-1238
CrossRef154
R. W. Johnson, J. McElhaney. (2009) Postherpetic neuralgia in the elderly. International Journal of Clinical Practice 63:9, 1386-1391
CrossRef155
Honorio T. Benzon, Kiran Chekka, Amit Darnule, Brian Chung, Oscar Wille, Khalid Malik. (2009) Evidence-Based Case Report. Regional Anesthesia and Pain Medicine 34:5, 514-521
CrossRef156
Ronald R. White, Greg Lenhart, Puneet K. Singhal, Ralph P. Insinga, Robbin F. Itzler, James M. Pellissier, Arthur W. Segraves. (2009) Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health Plans. PharmacoEconomics 27:9, 781-792
CrossRef157
Markus Braun-Falco, Marco Hoffmann. (2009) Herpes zoster with progression to acute varicella zoster virus-meningoencephalitis. International Journal of Dermatology 48:8, 834-839
CrossRef158
Brian E. McGeeney. (2009) Pharmacological Management of Neuropathic Pain in Older Adults: An Update on Peripherally and Centrally Acting Agents. Journal of Pain and Symptom Management 38:2, S15-S27
CrossRef159
Wolfgang Herr, Bodo Plachter. (2009) Cytomegalovirus and varicella–zoster virus vaccines in hematopoietic stem cell transplantation. Expert Review of Vaccines 8:8, 999-1021
CrossRef160
Patricia Bruckenthal, M. Carrington Reid, Lori Reisner. (2009) Special Issues in the Management of Chronic Pain in Older Adults. Pain Medicine 10:S2, S67-S78
CrossRef161
M. Amparo Torrecilla Rojas, Fermín García Rodríguez, Manuel Rodríguez Rodríguez, Josefa Ruiz Fernández. (2009) La vacunación frente a herpes zóster. Atención Primaria 41:7, 424-425
CrossRef162
Marc E. Weksler, Graham Pawelec, Claudio Franceschi. (2009) Immune therapy for age-related diseases. Trends in Immunology 30:7, 344-350
CrossRef163
Ruth Harbecke, Michael N. Oxman, Beth A. Arnold, Charlotte Ip, Gary R. Johnson, Myron J. Levin, Lawrence D. Gelb, Kenneth E. Schmader, Stephen E. Straus, Hui Wang, Peter F. Wright, Constance T. Pachucki, Anne A. Gershon, Robert D. Arbeit, Larry E. Davis, Michael S. Simberkoff, Adriana Weinberg, Heather M. Williams, Carol Cheney, Luba Petrukhin, Katalin G. Abraham, Alan Shaw, Susan Manoff, Joseph M. Antonello, Tina Green, Yue Wang, Charles Tan, Paul M. Keller, . (2009) A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. Journal of Medical Virology 81:7, 1310-1322
CrossRef164
Wilbur H. Chen, Bernard F. Kozlovsky, Rita B. Effros, Beatrix Grubeck-Loebenstein, Robert Edelman, Marcelo B. Sztein. (2009) Vaccination in the elderly: an immunological perspective. Trends in Immunology 30:7, 351-359
CrossRef165
Anne A. Gershon, Myron J. Levin, Adriana Weinberg, Lin-Yee Song, Philip S. LaRussa, Sharon P. Steinberg, Patterson Bartlett. (2009) A PHASE I–II STUDY OF LIVE ATTENUATED VARICELLA-ZOSTER VIRUS VACCINE TO BOOST IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN WITH PREVIOUS VARICELLA. The Pediatric Infectious Disease Journal 28:7, 653-655
CrossRef166
Georgios Trimis, Stamatis Gregoriou, Dimos Florakis, Dimitrios Rigopoulos. (2009) Can varicella immunization change the course of herpes zoster while herpes zoster vaccine is underway?. Expert Review of Dermatology 4:3, 219-224
CrossRef167
Irene M. Wielawski. (2009) Shingles and the Vaccine to Prevent It. AJN, American Journal of Nursing 109:6, 63-65
CrossRef168
Jennifer Turnbull, Lorraine Harper. (2009) Adverse effects of therapy for ANCA-associated vasculitis. Best Practice & Research Clinical Rheumatology 23:3, 391-401
CrossRef169
Sum Lam, Tomasz Z. Jodlowski. (2009) <b>Vaccines for Older Adults</b>. The Consultant Pharmacist 24:5, 380-391
CrossRef170
Janet E McElhaney. (2009) Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Review of Vaccines 8:5, 593-606
CrossRef171
Ivan S. F. Chan, William W. B. Wang. (2009) On Analysis of the Difference of Two Exposure-Adjusted Poisson Rates with Stratification: From Asymptotic to Exact Approaches. Statistics in Biosciences 1:1, 65-79
CrossRef172
Heidi M. Crane, Shireesha Dhanireddy, H. Nina Kim, Christian Ramers, Timothy H. Dellit, Mari M. Kitahata, Robert D. Harrington. (2009) Optimal timing of routine vaccination in HIV-infected persons. Current HIV/AIDS Reports 6:2, 93-99
CrossRef173
Qifu Li, Yun Zhang, Muke Zhou, Dong Zhou, Li He, Li He. 2009. Vaccination for preventing postherpetic neuralgia. .
CrossRef174
Jean-Pierre Michel, Christian Chidiac, Beatrix Grubeck-Loebenstein, Robert W. Johnson, Paul Henri Lambert, Stefania Maggi, Robert Moulias, Karl Nicholson, Hans Werner. (2009) Advocating Vaccination of Adults Aged 60 Years and Older in Western Europe:. Rejuvenation Research 12:2, 127-136
CrossRef175
Robert H. Dworkin, Richard L. Barbano, Stephen K. Tyring, Robert F. Betts, Michael P. McDermott, Janet Pennella-Vaughan, Gary J. Bennett, Erhan Berber, John W. Gnann, Carrie Irvine, Cornelia Kamp, Karl Kieburtz, Mitchell B. Max, Kenneth E. Schmader. (2009) A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 142:3, 209-217
CrossRef176
Brenda L. Bartlett, Stephen K. Tyring. (2009) Safety and efficacy of vaccines. Dermatologic Therapy 22:2, 97-103
CrossRef177
Kevin P. High, Suzanne F. Bradley, Stefan Gravenstein, David R. Mehr, Vincent J. Quagliarello, Chesley Richards, Thomas T. Yoshikawa. (2009) Clinical Practice Guideline for the Evaluation of Fever and Infection in Older Adult Residents of Long-Term Care Facilities: 2008 Update by the Infectious Diseases Society of America. Journal of the American Geriatrics Society 57:3, 375-394
CrossRef178
Rosella Creed, Anita Satyaprakash, Parisa Ravanfar. (2009) Varicella zoster vaccines. Dermatologic Therapy 22:2, 143-149
CrossRef179
S. Gurunathan, R. El Habib, L. Baglyos, C. Meric, S. Plotkin, B. Dodet, L. Corey, J. Tartaglia. (2009) Use of predictive markers of HIV disease progression in vaccine trials. Vaccine 27:14, 1997-2015
CrossRef180
P. Sampathkumar, L. A. Drage, D. P. Martin. (2009) Herpes Zoster (Shingles) and Postherpetic Neuralgia. Mayo Clinic Proceedings 84:3, 274-280
CrossRef181
Myron J Levin, Jeffrey P Anderson, George R Seage, Paige L Williams. (2009) Short-Term and Long-Term Effects of Highly Active Antiretroviral Therapy on the Incidence of Herpes Zoster in HIV-Infected Children. JAIDS Journal of Acquired Immune Deficiency Syndromes 50:2, 182-191
CrossRef182
Peng-jun Lu, Gary L. Euler, Aisha O. Jumaan, Rafael Harpaz. (2009) Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: Uptake of the first new vaccine to target seniors. Vaccine 27:6, 882-887
CrossRef183
Leonardo Fuks, David Shitrit, Benjamin D. Fox, Anat Amital, Yael Raviv, Ilana Bakal, Mordechai R. Kramer. (2009) Herpes Zoster After Lung Transplantation: Incidence, Timing, and Outcome. The Annals of Thoracic Surgery 87:2, 423-426
CrossRef184
Esther Grinfeld, Alan Ross, Thorsten Forster, Peter Ghazal, Peter G. E. Kennedy. (2009) Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with Parental Oka strain using long oligonucleotide microarrays. Virus Genes 38:1, 19-29
CrossRef185
A.J. van Hoek, N. Gay, A. Melegaro, W. Opstelten, W.J. Edmunds. (2009) Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27:9, 1454-1467
CrossRef186
Kevin P. High, Suzanne F. Bradley, Stefan Gravenstein, David R. Mehr, Vincent J. Quagliarello, Chesley Richards, Thomas T. Yoshikawa. (2009) Clinical Practice Guideline for the Evaluation of Fever and Infection in Older Adult Residents of Long‐Term Care Facilities: 2008 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 48:2, 149-171
CrossRef187
Tetsuo Koshizuka, Yasuko Mori. (2009) The research for development of polyvalent lived vaccine based on current varicella vaccine. Drug Delivery System 24:6, 592-598
CrossRef188
Alicia N. Stein, Helena Britt, Christopher Harrison, E. Lynne Conway, Anthony Cunningham, C. Raina MacIntyre. (2009) Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 27:4, 520-529
CrossRef189
Mark R. Schleiss. (2009) Persistent and Recurring Viral Infections: The Human Herpesviruses. Current Problems in Pediatric and Adolescent Health Care 39:1, 7-23
CrossRef190
Paul J. Christo, Brian D. Cauley. 2009. POSTHERPETIC NEURALGIA. , 261-267.
CrossRef191
Miranda A. Farage, Kenneth W. Miller, Enzo Berardesca, Howard I. Maibach. (2009) Clinical Implications of Aging Skin. American Journal of Clinical Dermatology 10:2, 73-86
CrossRef192
A. GAUTHIER, J. BREUER, D. CARRINGTON, M. MARTIN, V. RÉMY. (2009) Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiology and Infection 137:01, 38
CrossRef193
Yoshizo ASANO. (2009) A live attenuated varicella vaccine. Uirusu 59:2, 249-256
CrossRef194
Don Gilden, Maria A Nagel, Ravi Mahalingam, Niklaus H Mueller, Elizabeth A Brazeau, Subbiah Pugazhenthi, Randall J Cohrs. (2009) Clinical and molecular aspects of varicella zoster virus infection. Future Neurology 4:1, 103-117
CrossRef195
Wim Opstelten, Gerrit A. van Essen, Eelko Hak. (2009) Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine 27:2, 192-196
CrossRef196
S. Porter. 2009. Viral and fungal infections of the oral cavity. , 19-50.
CrossRef197
Stephanie Studenski, Luigi Ferrucci, Neil M. Resnick. 2009. Geriatrics. , 477-495.
CrossRef198
Nizar Ajjan. 2009. Acquisitions récentes en matière de vaccinations et vaccins du futur. , 207-301.
CrossRef199
Denise D. Wilson. (2008) Herpes Zoster. Advances in Skin & Wound Care 21:12, 582-588
CrossRef200
AM Geretti, . (2008) British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Medicine 9:10, 795-848
CrossRef201
Philippe Beutels, Paul A Scuffham, C Raina MacIntyre. (2008) Funding of drugs: do vaccines warrant a different approach?. The Lancet Infectious Diseases 8:11, 727-733
CrossRef202
Kay Sadaoka, Shigefumi Okamoto, Yasuyuki Gomi, Takeshi Tanimoto, Toyokazu Ishikawa, Tetsushi Yoshikawa, Yoshizo Asano, Koichi Yamanishi, Yasuko Mori. (2008) Measurement of Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity: Comparison between VZV Skin Test and Interferon‐γ Enzyme‐Linked Immunospot Assay. The Journal of Infectious Diseases 198:9, 1327-1333
CrossRef203
Yasuyuki Gomi, Takao Ozaki, Naoko Nishimura, Atsushi Narita, Michio Suzuki, Jaekun Ahn, Naoko Watanabe, Norio Koyama, Hajime Ushida, Naoko Yasuda, Kazumasa Nakane, Keiji Funahashi, Isao Fuke, Akihisa Takamizawa, Toyokazu Ishikawa, Koichi Yamanishi, Michiaki Takahashi. (2008) DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine. Vaccine 26:44, 5627-5632
CrossRef204
Martina Sester, Barbara C. Gärtner, Matthias Girndt, Urban Sester. (2008) Vaccination of the solid organ transplant recipient. Transplantation Reviews 22:4, 274-284
CrossRef205
Lisa A. Jackson, Meredith A. Reynolds, Rafael Harpaz. (2008) Hospitalizations to Treat Herpes Zoster in Older Adults: Causes and Validated Rates. Clinical Infectious Diseases 47:6, 754-759
CrossRef206
Vasilios German, Georgios Sakagiannis, Georgios Margaritis, Matthew E. Falagas. (2008) Inka Dinka Don't. The American Journal of Medicine 121:9, 772-773
CrossRef207
A. Volpi, A. Gatti, F. Pica, S. Bellino, L.T. Marsella, A.F. Sabato. (2008) Clinical and psychosocial correlates of post-herpetic neuralgia. Journal of Medical Virology 80:9, 1646-1652
CrossRef208
M. Najafzadeh, M. Sadatsafavi, C.A. Marra. (2008) Vaccine 26:41, 5244
CrossRef209
Rita B. Effros, Courtney V. Fletcher, Kelly Gebo, Jeffrey B. Halter, William R. Hazzard, Frances McFarland Horne, Robin E. Huebner, Edward N. Janoff, Amy C. Justice, Daniel Kuritzkes, Susan G. Nayfield, Susan F. Plaeger, Kenneth E. Schmader, John R. Ashworth, Christine Campanelli, Charles P. Clayton, Beth Rada, Nancy F. Woolard, Kevin P. High. (2008) Aging and Infectious Diseases: Workshop on HIV Infection and Aging: What Is Known and Future Research Directions. Clinical Infectious Diseases 47:4, 542-553
CrossRef210
Seok Jin Kim, Kihyun Kim, Byung Soo Kim, Hyo-Jin Lee, Hawk Kim, Na-Ri Lee, Seung-Hyun Nam, Jung Hye Kwon, Hyo Jung Kim, Sang Kyun Sohn, Jong-Ho Won, Jae Hoon Lee, Cheolwon Suh, Sung-Soo Yoon, Hye Jin Kim, Inho Kim, Young-Rok Do, Won-Sik Lee, Young-Don Joo, Ho Jin Shin. (2008) Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia 8:4, 237-240
CrossRef211
Stanley A. Plotkin. (2008) Vaccines: Correlates of Vaccine‐Induced Immunity. Clinical Infectious Diseases 47:3, 401-409
CrossRef212
Marissa B Wilck, Lindsey R Baden. (2008) Vaccination after stem cell transplant: a review of recent developments and implications for current practice. Current Opinion in Infectious Diseases 21:4, 399-408
CrossRef213
Niklaus H. Mueller, Donald H. Gilden, Randall J. Cohrs, Ravi Mahalingam, Maria A. Nagel. (2008) Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease, and Latency. Neurologic Clinics 26:3, 675-697
CrossRef214
Kristine Macartney, Peter McIntyre, Kristine Macartney. 2008. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. .
CrossRef215
Suzanna LR McDonald, Judith Breuer. 2008. Varicella Zoster: Virus and Disease. .
CrossRef216
Miriam Wittek. (2008) Fortschritte in der Diagnostik von Varizella Zoster und Stellenwert der Impfung / Advances in varicella zoster virus diagnostics and importance of vaccination. LaboratoriumsMedizin 32:4, 266-273
CrossRef217
Ted Cohen, Marc Lipsitch. (2008) Too Little of a Good Thing. Epidemiology 19:4, 588-589
CrossRef218
Miriam Wittek. (2008) Advances in the diagnostics of Varizella zoster virus and importance of vaccination 1. LaboratoriumsMedizin 32:4, ---
CrossRef219
Adolfo C Fernandez-Obregon, Dhrumil Shah, Amanda I Howell, Imane Tiyal Bentahar, Lester Carrodeguas, Arifa Siddiqui, Julia A Ejiogu. (2008) Challenges in anti-infective therapy for skin conditions: part 1. Expert Review of Dermatology 3:3, 367-394
CrossRef220
William P. Carter, Carl A. Germann, Michael R. Baumann. (2008) Ophthalmic diagnoses in the ED: herpes zoster ophthalmicus. The American Journal of Emergency Medicine 26:5, 612-617
CrossRef221
Eva López, Antònia Agustí. (2008) Prevención de la neuralgia postherpética. Medicina Clínica 130:20, 794-796
CrossRef222
Rajesh Kumar, Edith A Burns. (2008) Age-related decline in immunity: implications for vaccine responsiveness. Expert Review of Vaccines 7:4, 467-479
CrossRef223
T. Glück, U. Müller‐Ladner. (2008) Vaccines: Vaccination in Patients with Chronic Rheumatic or Autoimmune Diseases. Clinical Infectious Diseases 46:9, 1459-1465
CrossRef224
James Norman, Douglas Politz. (2008) Shingles (Varicella Zoster) Outbreaks in Patients with Hyperparathyroidism and Their Relationship to Hypercalcemia. Clinical Infectious Diseases 46:9, 1452-1454
CrossRef225
Warren R. Heymann. (2008) The herpes zoster vaccine. Journal of the American Academy of Dermatology 58:5, 872-873
CrossRef226
Rafael Benoliel, Eli Eliav. (2008) Neuropathic Orofacial Pain. Oral and Maxillofacial Surgery Clinics of North America 20:2, 237-254
CrossRef227
Kelly K. Curtis, Megan K. Connolly, Donald W. Northfelt. (2008) Live, Attenuated Varicella Zoster Vaccination of an Immunocompromised Patient. Journal of General Internal Medicine 23:5, 648-649
CrossRef228
Birgit Weinberger, Dietmar Herndler‐Brandstetter, Angelika Schwanninger, Daniela Weiskopf, Beatrix Grubeck‐Loebenstein. (2008) Biology of Immune Responses to Vaccines in Elderly Persons. Clinical Infectious Diseases 46:7, 1078-1084
CrossRef229
Robert H. Dworkin, Richard White, Alec B. O’Connor, Kevin Hawkins. (2008) Health Care Expenditure Burden of Persisting Herpes Zoster Pain. Pain Medicine 9:3, 348-353
CrossRef230
Ramón San Miguel, Ana María López-González, Eduardo Sanchez-Iriso, Javier Mar, Juan M. Cabasés. (2008) Measuring health-related quality of life in drug clinical trials: is it given due importance?. Pharmacy World & Science 30:2, 154-160
CrossRef231
Giuseppina Candore, Carmela Rita Balistreri, Giuseppina Colonna-Romano, Maria Paola Grimaldi, Domenico Lio, Florinda Listi', Letizia Scola, Sonya Vasto, Calogero Caruso. (2008) Immunosenescence and Anti-Immunosenescence Therapies: The Case of Probiotics. Rejuvenation Research 11:2, 425-432
CrossRef232
M. J. Levin, M. N. Oxman, J. H. Zhang, G. R. Johnson, H. Stanley, A. R. Hayward, M. J. Caulfield, M. R. Irwin, J. G. Smith, J. Clair, I. S. F. Chan, H. Williams, R. Harbecke, R. Marchese, S. E. Straus, A. Gershon, A. Weinberg, . (2008) Varicella‐Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine. The Journal of Infectious Diseases 197:6, 825-835
CrossRef233
Sophie Hambleton, Sharon P. Steinberg, Philip S. LaRussa, Eugene D. Shapiro, Anne A. Gershon. (2008) Risk of Herpes Zoster in Adults Immunized with Varicella Vaccine. The Journal of Infectious Diseases 197:s2, S196-S199
CrossRef234
Bruce H Thiers. (2008) What's new in dermatologic therapy. Dermatologic Therapy 21:2, 142-149
CrossRef235
Christine Orlova Urman, Alice B. Gottlieb. (2008) New viral vaccines for dermatologic disease. Journal of the American Academy of Dermatology 58:3, 361-370
CrossRef236
Laura P. Hurley, Rafael Harpaz, Matthew F. Daley, Lori A. Crane, Brenda L. Beaty, Jennifer Barrow, Christine Babbel, Mona Marin, John F. Steiner, Arthur Davidson, L. Miriam Dickinson, Allison Kempe. (2008) National Survey of Primary Care Physicians Regarding Herpes Zoster and the Herpes Zoster Vaccine. The Journal of Infectious Diseases 197:s2, S216-S223
CrossRef237
Anne A. Gershon, Samuel L. Katz. (2008) Perspective on Live Varicella Vaccine. The Journal of Infectious Diseases 197:s2, S242-S245
CrossRef238
Kenneth Schmader, John W. Gnann, Jr., C. Peter Watson. (2008) The Epidemiological, Clinical, and Pathological Rationale for the Herpes Zoster Vaccine. The Journal of Infectious Diseases 197:s2, S207-S215
CrossRef239
Judith Breuer. (2008) Herpes Zoster: New Insights Provide an Important Wake‐Up Call for Management of Nosocomial Transmission. The Journal of Infectious Diseases 197:5, 635-637
CrossRef240
Michael N. Oxman, Myron J. Levin, . (2008) Vaccination against Herpes Zoster and Postherpetic Neuralgia. The Journal of Infectious Diseases 197:s2, S228-S236
CrossRef241
Meredith A. Reynolds, Sandra S. Chaves, Rafael Harpaz, Adriana S. Lopez, Jane F. Seward. (2008) The Impact of the Varicella Vaccination Program on Herpes Zoster Epidemiology in the United States: A Review. The Journal of Infectious Diseases 197:s2, S224-S227
CrossRef242
Jeffrey I. Cohen. (2008) Strategies for Herpes Zoster Vaccination of Immunocompromised Patients. The Journal of Infectious Diseases 197:s2, S237-S241
CrossRef243
Michael R. Irwin. (2008) Human psychoneuroimmunology: 20 Years of discovery. Brain, Behavior, and Immunity 22:2, 129-139
CrossRef244
Kayode A. Williams, Robert W. Hurley, Elaina E. Lin, Christopher L. Wu. 2008. Neuropathic Pain Syndromes. , 427-443.
CrossRef245
Oriol Manuel, Deepali Kumar, Lianne G. Singer, Isabel Cobos, Atul Humar. (2008) Incidence and Clinical Characteristics of Herpes Zoster After Lung Transplantation. The Journal of Heart and Lung Transplantation 27:1, 11-16
CrossRef246
Elon Eisenberg. (2008) European Pain Management Discussion Forum. Journal of Pain and Palliative Care Pharmacotherapy 22:3, 235-238
CrossRef247
Koichi Yamanishi. (2008) Perspective for vaccine against infectious diseases. Drug Delivery System 23:2, 151-158
CrossRef248
Tracy A Lieu, Ismael Ortega-Sanchez, G Thomas Ray, Donna Rusinak, W Katherine Yih, Peter W Choo, Irene Shui, Ken Kleinman, Rafael Harpaz, Lisa A Prosser. (2008) Community and Patient Values for Preventing Herpes Zoster. PharmacoEconomics 26:3, 235-249
CrossRef249
Adnan Said, Nasia Safdar, Jennifer Wells, Michael R. Lucey. 2008. Liver Disease in Renal Transplant Recipients. , 508-533.
CrossRef250
Woo Seok Sim, Jin Hwan Choi, Kyung Ream Han, Yong Chul Kim. (2008) Treatment of Herpes Zoster and Postherpetic Neuralgia. The Korean Journal of Pain 21:2, 93
CrossRef251
A. A. Gershon. (2008) Varicella-Zoster Virus Infections. Pediatrics in Review 29:1, 5-11
CrossRef252
Robert W Johnson, Gunnar Wasner, Patricia Saddier, Ralf Baron. (2008) Herpes Zoster and Postherpetic Neuralgia. Drugs & Aging 25:12, 991-1006
CrossRef253
W. Lawrence Drew, Kim S. Erlich. 2008. Management of Herpesvirus Infections (Cytomegalovirus, Herpes Simplex Virus, and Varicella-Zoster Virus). , 437-461.
CrossRef254
Karen D. Sims, Emily A. Blumberg. 2008. Prevention and Treatment of Infection in Kidney Transplant Recipients. , 1034-1046.
CrossRef255
R. K. Avery, M. Michaels. (2008) Update on Immunizations in Solid Organ Transplant Recipients: What Clinicians Need to Know. American Journal of Transplantation 8:1, 9-14
CrossRef256
Luis Salleras Sanmartí, Monserrat Salleras Redonnet, Andrés Prat, Patricio Garrido, Ángela Domínguez. (2008) Vacunas frente al virus de la varicela zóster. Enfermedades Infecciosas y Microbiología Clínica 26, 29-47
CrossRef257
Ivan S. F. Chan. 2007. Vaccine. .
CrossRef258
Jeffrey M. Weinberg. (2007) Herpes zoster: Epidemiology, natural history, and common complications. Journal of the American Academy of Dermatology 57:6, S130-S135
CrossRef259
Robert Johnson, Janet McElhaney, Biagio Pedalino, Myron Levin. (2007) Prevention of herpes zoster and its painful and debilitating complications. International Journal of Infectious Diseases 11, S43-S48
CrossRef260
M. Brisson, J. M. Pellissier, M. J. Levin. (2007) Cost-Effectiveness of Herpes Zoster Vaccine: Flawed Assumptions Regarding Efficacy against Postherpetic Neuralgia. Clinical Infectious Diseases 45:11, 1527-1529
CrossRef261
Mazen S. Bader. (2007) Immunization for the Elderly. The American Journal of the Medical Sciences 334:6, 481-486
CrossRef262
Robert F. Betts. (2007) Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia. Journal of the American Academy of Dermatology 57:6, S143-S147
CrossRef263
W A Orenstein, G T Mootrey, K Pazol, A R Hinman. (2007) Financing Immunization of Adults in the United States. Clinical Pharmacology & Therapeutics 82:6, 764-768
CrossRef264
D. C. Braun, A. C. Birch, D. Benson, R. F. Stein, A. Nordlund. (2007) Helioseismic Holography of Simulated Solar Convection and Prospects for the Detection of Small‐Scale Subsurface Flows. The Astrophysical Journal 669:2, 1395-1405
CrossRef265
Robert W Johnson, Gunnar Wasner, Patricia Saddier, Ralf Baron. (2007) Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Review of Neurotherapeutics 7:11, 1581-1595
CrossRef266
Israel Steiner, Peter GE Kennedy, Andrew R Pachner. (2007) The neurotropic herpes viruses: herpes simplex and varicella-zoster. The Lancet Neurology 6:11, 1015-1028
CrossRef267
James M. Pellissier, Marc Brisson, Myron J. Levin. (2007) Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 25:49, 8326-8337
CrossRef268
B. P. Yawn, P. Saddier, P. C. Wollan, J. L. St. Sauver, M. J. Kurland, L. S. Sy. (2007) A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction. Mayo Clinic Proceedings 82:11, 1341-1349
CrossRef269
Qifu Li, Li He, Quanwei Zhang, Muke Zhou, Dong Zhou, Li He. 2007. Antiviral treatment for preventing postherpetic neuralgia. .
CrossRef270
V. Erard, K. A. Guthrie, C. Varley, J. Heugel, A. Wald, M. E. D. Flowers, L. Corey, M. Boeckh. (2007) One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110:8, 3071-3077
CrossRef271
Boris Kerzner, Alexander V. Murray, Eric Cheng, Rudy Ifle, Peter R. Harvey, Mark Tomlinson, Julie L. Barben, Kimberly Rarrick, Jon E. Stek, Mi-Ok Chung, Florian P. Schödel, William W. B. Wang, Jin Xu, Ivan S. F. Chan, Jeffrey L. Silber, Katia Schlienger. (2007) Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older. Journal of the American Geriatrics Society 55:10, 1499-1507
CrossRef272
Alexander Doroshenko, Scott A Halperin. (2007) Vaccination: the importance of herd immunity. Pediatric Health 1:1, 35-42
CrossRef273
Lily N. Clark, Mark Lebwohl. (2007) Recent advances in medical dermatology. International Journal of Dermatology 46:10, 1005-1010
CrossRef274
Julie Patterson-Bartlett, Myron J. Levin, Nancy Lang, Florian P. Schödel, Rupert Vessey, Adriana Weinberg. (2007) Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 25:41, 7087-7093
CrossRef275
Yi-Wei Tang, Hatim T. Allawi, Marlene DeLeon-Carnes, Haijing Li, Stephen P. Day, D. Scott Schmid. (2007) Detection and differentiation of wild-type and vaccine mutant varicella-zoster viruses using an Invader Plus® method. Journal of Clinical Virology 40:2, 129-134
CrossRef276
Tin Han Htwe, Adnan Mushtaq, Sherry B. Robinson, Richard B. Rosher, Nancy Khardori. (2007) Infection in the Elderly. Infectious Disease Clinics of North America 21:3, 711-743
CrossRef277
Paul J. Drinka. (2007) How Should Nursing Homes Use Vaccine to Prevent Zoster?. Journal of the American Medical Directors Association 8:7, 419-420
CrossRef278
Camille Nelson Kotton. (2007) Nailing down the shingles in IBD. Inflammatory Bowel Diseases 13:9, 1178-1179
CrossRef279
Mark D. Pescovitz. (2007) Antiviral Therapies for Cytomegalovirus in Solid-Organ Transplantation. Transplantation 84:Supplement, S2-S6
CrossRef280
Yang Ou, Vicki Traina-Dorge, Kara A. Davis, Wayne L. Gray. (2007) Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys. Virology 364:2, 291-300
CrossRef281
Eun Jeong Kwak, Robin K Avery. (2007) Strategies for the prevention of infectious complications after renal transplantation. Current Opinion in Organ Transplantation 12:4, 362-370
CrossRef282
Robert H. Dworkin, Richard White, Alec B. O'Connor, Onur Baser, Kevin Hawkins. (2007) Healthcare Costs of Acute and Chronic Pain Associated with a Diagnosis of Herpes Zoster. Journal of the American Geriatrics Society 55:8, 1168-1175
CrossRef283
A. A. GERSHON. (2007) Vaccination to prevent zoster in the elderly. Epidemiology and Infection 135:06, 883
CrossRef284
Gerd Gros, Hans‐Wilhelm Doerr, Maria Grazia Revello. (2007) Herpes Zoster: Recent Aspects of Diagnosis and Control:Herpes Zoster: Recent Aspects of Diagnosis and Control. Clinical Infectious Diseases 45:3, 408-408
CrossRef285
Kenneth Schmader. (2007) Herpes Zoster and Postherpetic Neuralgia in Older Adults. Clinics in Geriatric Medicine 23:3, 615-632
CrossRef286
Edgar Turner Overton. (2007) An overview of vaccinations in HIV. Current HIV/AIDS Reports 4:3, 105-113
CrossRef287
(2007) Varicella–Zoster Vaccine. New England Journal of Medicine 357:1, 88-90
Full Text288
Rachel Espiritu, Michael Rich. (2007) Herpes Zoster Encephalitis. Infectious Diseases in Clinical Practice 15:4, 284-288
CrossRef289
Timo Vesikari, Catherine Sadzot-Delvaux, Bernard Rentier, Anne Gershon. (2007) Increasing Coverage and Efficiency of Measles, Mumps, and Rubella Vaccine and Introducing Universal Varicella Vaccination in Europe. The Pediatric Infectious Disease Journal 26:7, 632-638
CrossRef290
Kenneth E. Schmader, Richard Sloane, Carl Pieper, Paul M. Coplan, Alexander Nikas, Patricia Saddier, Ivan S. F. Chan, Peter Choo, Myron J. Levin, Gary Johnson, Heather M. Williams, Michael N. Oxman. (2007) The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older Adults. The Clinical Journal of Pain 23:6, 490-496
CrossRef291
Kimberly A. Cappuzzo, René Roberts Krogsund. (2007) <b>Postherpetic Neuralgia in an Elderly Patient</b>. The Consultant Pharmacist 22:7, 593-598
CrossRef292
Denise R Kockler, Michelle W McCarthy. (2007) Zoster Vaccine Live. Pharmacotherapy 27:7, 1013-1019
CrossRef293
Birger Trollfors. (2007) General vaccination of children against varicella?-Yes!. Acta Paediatrica 96:6, 794-795
CrossRef294
Gary Laustsen, Tim Neilson. (2007) Prevent Shingles with Zostavax. The Nurse Practitioner 32:6, 6-7
CrossRef295
M. B. Rothberg, A. Virapongse, K. J. Smith. (2007) Cost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Clinical Infectious Diseases 44:10, 1280-1288
CrossRef296
Alan E. Simon, Albert W. Wu, Philip W. Lavori, Jeremy Sugarman. (2007) Preventive Misconception. American Journal of Preventive Medicine 32:5, 370-374
CrossRef297
Po-yuan Wu, Yu-Chuan Li, Hong-Dar Isaac Wu. (2007) Risk factors for chickenpox incidence in Taiwan from a large-scale computerized database. International Journal of Dermatology 46:4, 362-366
CrossRef298
Caren McHenry Martin, Lauri G. Saleeby. (2007) <b>All Pain Is Not the Same: An Overview of Neuropathic Pain in the Elderly</b>. The Consultant Pharmacist 22:4, 283-294
CrossRef299
G. G. Miller, J. S. Dummer. (2007) Herpes Simplex and Varicella Zoster Viruses: Forgotten but Not Gone. American Journal of Transplantation 7:4, 741-747
CrossRef300
Alexandra Y. Zhang, Craig A. Elmets, William L. Camp, Boni E. Elewski. (2007) New opportunities in preventative dermatology: How far should we go?. Journal of the American Academy of Dermatology 56:4, 675-676
CrossRef301
Juan Jorge Manriquez, Maria Francisca Villouta, Hywel C. Williams. (2007) Evidence-based dermatology: Number needed to treat and its relation to other risk measures. Journal of the American Academy of Dermatology 56:4, 664-671
CrossRef302
Janne Ludwig, Ralf Baron. (2007) Prevention and treatment of postherpetic neuralgia. Aging Health 3:2, 223-230
CrossRef303
Antonio Volpi, Antonio Gatti, Giuseppe Serafini, Bruno Costa, Barbara Suligoi, Francesca Pica, Luigi T. Marsella, Elisabetta Sabato, Alessandro F. Sabato. (2007) Clinical and psychosocial correlates of acute pain in herpes zoster. Journal of Clinical Virology 38:4, 275-279
CrossRef304
Michael R. Irwin, Richard Olmstead, Michael N. Oxman. (2007) Augmenting Immune Responses to Varicella Zoster Virus in Older Adults: A Randomized, Controlled Trial of Tai Chi. Journal of the American Geriatrics Society 55:4, 511-517
CrossRef305
Hassan Vally, Gary K. Dowse, Keith Eastwood, Scott Cameron. (2007) An outbreak of chickenpox at a child care centre in Western Australia. Costs to the community and implications for vaccination policy. Australian and New Zealand Journal of Public Health 31:2, 113-119
CrossRef306
Kimberlin, David W., Whitley, Richard J., . (2007) Varicella–Zoster Vaccine for the Prevention of Herpes Zoster. New England Journal of Medicine 356:13, 1338-1343
Full Text307
Karin L. Petersen, Hans Gustav Thyregod, Michael C. Rowbotham. (2007) Response to the Letter to the Editor by Robert Dworkin. Pain 128:1-2, 190-192
CrossRef308
Michael A.O. Lewis, Vidya Sankar, Antoon De Laat, Rafael Benoliel. (2007) Management of neuropathic orofacial pain. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 103, S32.e1-S32.e24
CrossRef309
Robert W. Johnson, Andrew S.C. Rice. (2007) Pain following herpes zoster: The influence of changing population characteristics and medical developments. Pain 128:1-2, 3-5
CrossRef310
Robert H. Dworkin. (2007) Inadequate evidence for a revised definition of postherpetic neuralgia (PHN). Pain 128:1-2, 189-190
CrossRef311
N. Macaladad, T. Marcano, M. Guzman, J. Moya, F. Jurado, M. Thompson, C. Meechan, D. Li, K. Schlienger, I. Chan, J. Sadoff, F. Schödel, J.L. Silber. (2007) Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 25:11, 2139-2144
CrossRef312
Hans Gustav Thyregod, Michael C. Rowbotham, Michelle Peters, Jessica Possehn, Marlene Berro, Karin Lottrup Petersen. (2007) Natural history of pain following herpes zoster. Pain 128:1-2, 148-156
CrossRef313
Ian Gilron, Terence J Coderre. (2007) Emerging drugs in neuropathic pain. Expert Opinion on Emerging Drugs 12:1, 113-126
CrossRef314
Tamas Fülöp, Anis Larbi, Katsuiku Hirokawa, Eugenio Mocchegiani, Bruno Lesourd, Stephen Castle, Anders Wikby, Claudio Franceschi, Graham Pawelec. (2007) Immunosupportive therapies in aging. Clinical Interventions in Aging 2:1, 33-54
CrossRef315
Stephen K. Tyring, Francisco Diaz-Mitoma, Larry G. Padget, Margarita Nunez, Gregory Poland, William M. Cassidy, Nickoya D. Bundick, Jianjun Li, Ivan S.F. Chan, Jon E. Stek, Paula W. Annunziato. (2007) Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine 25:10, 1877-1883
CrossRef316
Donald H Gilden, Ravi Mahalingam, Randall J Cohrs, Kenneth L Tyler. (2007) Herpesvirus infections of the nervous system. Nature Clinical Practice Neurology 3:2, 82-94
CrossRef317
J.A. Stockman. (2007) A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Yearbook of Pediatrics 2007, 31-33
CrossRef318
Paul J Christo, Greg Hobelmann, David N Maine. (2007) Post-Herpetic Neuralgia in Older Adults. Drugs & Aging 24:1, 1-19
CrossRef319
R. H. Dworkin, R. W. Johnson, J. Breuer, J. W. Gnann, M. J. Levin, M. Backonja, R. F. Betts, A. A. Gershon, M. L. Haanpaa, M. W. McKendrick, T. J. Nurmikko, A. L. Oaklander, M. N. Oxman, D. P. Langston, K. L. Petersen, M. C. Rowbotham, K. E. Schmader, B. R. Stacey, S. K. Tyring, A. J. M. v. Wijck, M. S. Wallace, S. W. Wassilew, R. J. Whitley. (2007) Recommendations for the Management of Herpes Zoster. Clinical Infectious Diseases 44:Supplement 1, S1-S26
CrossRef320
Elaina G. Lindberg. (2007) Is There a Role for Herpes Zoster Vaccine in Chronic Pain Management?. Journal of Pain and Palliative Care Pharmacotherapy 21:3, 99-100
CrossRef321
Rita B. Effros. (2007) Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 25:4, 599-604
CrossRef322
Michael M Lederman, Adam Penn-Nicholson, Shelley F Stone, Scott F Sieg, Benigno Rodriguez. (2007) Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption. Current Opinion in HIV and AIDS 2:1, 56-61
CrossRef323
Ralph P Insinga, Robbin F Itzler, James M Pellissier. (2007) Acute/Subacute Herpes Zoster. PharmacoEconomics 25:2, 155-169
CrossRef324
Tony S. Ma, Tracie C. Collins, Gabriel Habib, Audrius Bredikis, Blase A. Carabello. (2007) Herpes Zoster and Its Cardiovascular Complications in the Elderly – Another Look at a Dormant Virus. Cardiology 107:1, 63-67
CrossRef325
Sashank Prasad, Steven Galetta. 2007. The Trigeminal Nerve. , 165-183.
CrossRef326
Thomas Hadjistavropoulos, Keela Herr, Dennis C. Turk, Perry G. Fine, Robert H. Dworkin, Robert Helme, Kenneth Jackson, Patricia A. Parmelee, Thomas E. Rudy, B. Lynn Beattie, John T. Chibnall, Kenneth D. Craig, Betty Ferrell, Bruce Ferrell, Roger B. Fillingim, Lucia Gagliese, Romayne Gallagher, Stephen J. Gibson, Elizabeth L. Harrison, Benny Katz, Francis J. Keefe, Susan J. Lieber, David Lussier, Kenneth E. Schmader, Raymond C. Tait, Debra K. Weiner, Jaime Williams. (2007) An Interdisciplinary Expert Consensus Statement on Assessment of Pain in Older Persons. The Clinical Journal of Pain 23:Supplement 1, S1-S43
CrossRef327
B. Salzberger. (2006) Antivirale Therapie. Der Internist 47:12, 1245-1250
CrossRef328
Wim Opstelten. (2006) Herpes zoster: geen roos zonder doorn. Huisarts en Wetenschap 49:12, 863-868
CrossRef329
Lesley Ann Saketkoo, Luis R. Espinoza. (2006) Impact of Biologic Agents on Infectious Diseases. Infectious Disease Clinics of North America 20:4, 931-961
CrossRef330
Gauree Gupta, Ebbing Lautenbach, James D. Lewis. (2006) Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 4:12, 1483-1490
CrossRef331
Siobhan L West, Richard W Newton, Eileen M Baildam, Andrew J Turner, Peter D Arkwright. (2006) Recurrent hemiplegia associated with cerebral vasculopathy following third trimester maternal herpes zoster infection. Developmental Medicine & Child Neurology 48:12, 991-993
CrossRef332
John J. Docherty, Thomas J. Sweet, Erin Bailey, Seth A. Faith, Tristan Booth. (2006) Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Research 72:3, 171-177
CrossRef333
Clemente Diaz, Pietro Dentico, Rocio Gonzalez, Rafael G. Mendez, Sandro Cinquetti, Julie L. Barben, Anna Harmon, Ira Chalikonda, Jeffrey G. Smith, Jon E. Stek, Andrew Robertson, Michael J. Caulfield, Luigi R. Biasio, Jeffrey L. Silber, Christina Y. Chan, Rupert Vessey, Jerald Sadoff, Ivan S.F. Chan, Holly Matthews, William Wang, Katia Schlienger, Florian P. Schödel. (2006) Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects ≥13 years of age. Vaccine 24:47-48, 6875-6885
CrossRef334
Nicholas Wood, Peter McIntyre, Melanie Wong. (2006) Vaccination for the paediatrician. Journal of Paediatrics and Child Health 42:11, 665-673
CrossRef335
Ulrich Heininger, Jane F Seward. (2006) Varicella. The Lancet 368:9544, 1365-1376
CrossRef336
Sawko W. Wassilew. (2006) Zoster-associated neuralgias. JDDG 4:10, 871-881
CrossRef337
Kenneth E. Schmader, Jack Twersky. 2006. Herpes Zoster, Cellulitis, and Scabies. , 277-296.
CrossRef338
Michael D. Hogue, Robert D. Arbeit, Lawrence D. Gelb. (2006) Reducing the Burden of Herpes Zoster and Postherpetic Neuralgia Through Vaccination. The Consultant Pharmacist 21:0, 1-24
CrossRef339
Rex Biedenbender, Stefan Gravenstein, Arvydas Ambrozaitis. 2006. Vaccinations. , 369-390.
CrossRef340
Hein J. Boot, Hester E. de Melker, Elly A. Stolk, G. Ardine de Wit, Tjeerd G. Kimman. (2006) Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine 24:37-39, 6288-6299
CrossRef341
Sarosh J. Motivala, Myron J. Levin, Michael N. Oxman, Michael R. Irwin. (2006) Impairments in Health Functioning and Sleep Quality in Older Adults with a History of Depression. Journal of the American Geriatrics Society 54:8, 1184-1191
CrossRef342
Lyn C Guenther. (2006) Herpes zoster and postherpetic neuralgia. Expert Review of Dermatology 1:4, 607-618
CrossRef343
Mark Holodniy. (2006) Prevention of shingles by varicella zoster virus vaccination. Expert Review of Vaccines 5:4, 431-443
CrossRef344
Pamela P. W. Lee, Tze-Leung Lee, Marco Hok-Kung Ho, Wilfred H. S. Wong, Yu-Lung Lau. (2006) Herpes Zoster in Juvenile-Onset Systemic Lupus Erythematosus. The Pediatric Infectious Disease Journal 25:8, 728-732
CrossRef345
Wolf Nurnberg, Burkhard Schneeweiss. (2006) Varicella vaccination update Neuere Erkenntnisse zur Varizellenimpfung. JDDG 4:7, 540-543
CrossRef346
David E. Michalik, Anne A. Gershon. (2006) Zoster vaccine for the elderly. Drug Discovery Today: Therapeutic Strategies 3:2, 237-241
CrossRef347
Dwight Moulin. (2006) Does acute pain associated with herpes zoster respond to treatment with gabapentin?. Nature Clinical Practice Neurology 2:6, 298-299
CrossRef348
Hester de Melker, Guy Berbers, Susan Hahné, Hans Rümke, Susan van den Hof, Ardine de Wit, Hein Boot. (2006) The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination. Vaccine 24:18, 3946-3952
CrossRef349
Velio Alvaro Bocci. (2006) Scientific and Medical Aspects of Ozone Therapy. State of the Art. Archives of Medical Research 37:4, 425-435
CrossRef350
Matthew M Davis. (2006) Successes and remaining challenges after 10 years of varicella vaccination in the USA. Expert Review of Vaccines 5:2, 295-302
CrossRef351
Alan R. Hinman, Walter A. Orenstein, Jeanne M. Santoli, Lance E. Rodewald, Stephen L. Cochi. (2006) VACCINE SHORTAGES: History, Impact, and Prospects for the Future*. Annual Review of Public Health 27:1, 235-259
CrossRef352
B. T. Rouse, S. D. Kaistha. (2006) A Tale of Two -Herpesviruses: Lessons for Vaccinologists. Clinical Infectious Diseases 42:6, 810-817
CrossRef353
Todd D. Gleeson, Mark R. Wallace, Sybil A. Tasker. (2006) Vaccination in patients with HIV infection. Current Infectious Disease Reports 8:2, 151-161
CrossRef354
Sharon Gatewood, Jean-Venable R. Goode, Dennis Stanley. (2006) Keeping Up-to-Date on Immunizations: A Framework and Review for Pharmacists. Journal of the American Pharmacists Association 46:2, 183-192
CrossRef355
Dietmar Herndler-Brandstetter, Daniel P. Cioca, Beatrix Grubeck-Loebenstein. (2006) Immunizations in the elderly: do they live up to their promise?. Wiener Medizinische Wochenschrift 156:5-6, 130-141
CrossRef356
A. Weinberg, S.P. Horslen, S.S. Kaufman, R. Jesser, A. DeVoll-Zabrocki, B.L. Fleckten, S. Kochanowicz, K.R. Seipel, M.J. Levin. (2006) Safety and Immunogenicity of Varicella-Zoster Virus Vaccine in Pediatric Liver and Intestine Transplant Recipients. American Journal of Transplantation 6:3, 565-568
CrossRef357
&NA;. (2006) Evaluation Form: Pediatric Infectious Disease Journal?? Supplement: Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases. The Pediatric Infectious Disease Journal 25:Supplement, S83-S84
CrossRef358
Judith L. Beizer, Edward H. Davidson. (2006) Journal Review. The Consultant Pharmacist 21:2, 147-150
CrossRef359
Larry E Davis. (2006) Neurological infections: clinical advances, global threats. The Lancet Neurology 5:1, 7-8
CrossRef360
Heather F. Gidding, Marc Brisson, C. Raina Macintyre, Margaret A. Burgess. (2005) Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia. Australian and New Zealand Journal of Public Health 29:6, 544-551
CrossRef361
KK Macartney, P Beutels, P McIntyre, MA Burgess. (2005) Varicella vaccination in Australia. Journal of Paediatrics and Child Health 41:11, 544-552
CrossRef362
Vincent W. Bramwell, Yvonne Perrie. (2005) The rational design of vaccines. Drug Discovery Today 10:22, 1527-1534
CrossRef363
K Grimwood. (2005) Another vaccine, another step forward?. Journal of Paediatrics and Child Health 41:11, 541-542
CrossRef364
R. G. Pebody. (2005) Universal varicella-zoster vaccination: is Europe ready?. International Journal of Clinical Practice 59:11, 1248-1250
CrossRef365
Israel Steiner. (2005) Can vaccinating older adults against varicella zoster virus prevent herpes zoster and postherpetic neuralgia?. Nature Clinical Practice Neurology 1:1, 18-19
CrossRef366
Susan S Chiu, Yu-Lung Lau. (2005) Review of the Varilrix™ varicella vaccine. Expert Review of Vaccines 4:5, 629-643
CrossRef367
(2005) A Vaccine to Prevent Herpes Zoster. New England Journal of Medicine 353:13, 1414-1415
Full Text368
B. Schneeweiß. (2005) Kinderimpfung gegen Varizellen. Monatsschrift Kinderheilkunde 153:9, 838-844
CrossRef369
Michael Houghton, Sergio Abrignani. (2005) Prospects for a vaccine against the hepatitis C virus. Nature 436:7053, 961-966
CrossRef370
James C. Johnston. (2005) LIABILITY OF THE EXPERT NEUROLOGIST. Neurology Today 5:8, 4
CrossRef371
P D Griffiths. (2005) A shot in the arm for immunotherapy. Reviews in Medical Virology 15:4, 215-217
CrossRef372
Gilden, Donald H., . (2005) Varicella–Zoster Virus Vaccine — Grown-ups Need It, Too. New England Journal of Medicine 352:22, 2344-2346
Full Text373
Arvin, Ann, . (2005) Aging, Immunity, and the Varicella–Zoster Virus. New England Journal of Medicine 352:22, 2266-2267
Full Text374
Marta Feldmesser. (2005) Prospects of vaccines for medically important fungi. Medical Mycology 43:7, 571-587
CrossRef375
Antonio Volpi, Gerd Gross, Jana Hercogova, Robert W Johnson. (2005) Current Management of Herpes Zoster. American Journal of Clinical Dermatology 6:5, 317-325
CrossRef376
Arturo Casadevall, Liise-anne Pirofski. (2005) Prospects of vaccines for medically important fungi Feasibility and prospects for a vaccine to prevent cryptococcosis. Medical Mycology 43:8, 667-680
CrossRef
- Letters
